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Abstract 
Approximately 15-20% of human cancers are associated with viral agents (Parkin, 2006). The 
human tumour virus Kaposi’s sarcoma associated herpesvirus (KSHV) is one such virus. It is the 
aetiological agent of the AIDS-defining malignancy Kaposi’s sarcoma (KS) and primary effusion 
lymphoma (PEL), and is linked to the development of multi-centric Castleman’s disease (MCD). 
As a herpesvirus, KSHV resides in a latent state within infected host cells, evading various innate 
and adaptive immune mechanisms. The widely expressed and highly conserved toll-like receptor 
(TLR) family plays a major role in binding of pathogen-associated molecular patterns (PAMPs), 
thus identifying pathogens and leading to the stimulation of relevant host immune responses. 
Members of the Herpesviridae family are known to act upon, interact with and/or be detected by 
certain TLRs. Based on this precedence, we have investigated the interaction of KSHV on 
human TLRs in the human epithelial kidney cell line, 293. We evaluated the initial effect of 
ectopic TLR expression on KSHV infection level and the effect of KSHV infection on ectopic 
TLR transcript levels. Using flow cytometry, we found that KSHV infection is sensitive to the 
expression of TLRs 2, 3, 4 and 5, presumably via KSHV PAMP recognition, and is not sensitive 
to the ectopic expression of TLRs 1, 6, 7, 8 and 9. Semi-quantitative PCR revealed that TLR 7 
mRNA levels are decreased by KSHV infection. We suggest that this result indicates that KSHV 
utilises some mechanism to decrease mRNA levels in order to evade potential antiviral responses 
triggered by the receptor. 
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Interactions between Kaposi’s Sarcoma-Associated Herpesvirus and Human Toll-like 
Receptors 
1. Introduction 
1.1 Kaposi’s sarcoma-associated herpesvirus (KSHV) and related malignancies 
KSHV, also known as human herpesvirus 8 (HHV8) (Chang et al. 1994), belongs to the 
lymphotrophic gamma (γ) herpesvirus subfamily. As a herpesvirus, KSHV consists of a large, 
double-stranded DNA (dsDNA) genome enclosed by an icosahedral capsid and has a life cycle 
that includes both lytic and latent stages. During latent infection, a restricted set of genes is 
expressed to ensure the virus’ survival within a host cell, whilst reducing detection by the host 
immune system. It is this characteristic, similar to other human tumour viruses, that is thought to 
contribute to the oncogenic nature of the virus (de Oliveira, 2007). KSHV is transmitted via 
saliva, and is the aetiological agent of Kaposi’s sarcoma (KS) and primary effusion lymphoma 
(PEL) (Bouvard et al. 2009). It is also strongly associated with the rare, lymphoproliferative 
malignancy multi-centric Castleman’s disease (MCD) (Soulier et al. 1995). KS is a malignant 
transformation of endothelial cells seen in immunosuppressed patients, middle-aged men of 
Mediterranean and Jewish descent, and in 60% of untreated AIDS patients (Parkin, 2006). The 
disease manifests as a tumour of lymphatic endothelial type cells, appearing as KSHV protein-
containing, and highly vascularised, lesions on the skin, mouth, gastro-intestinal tract and 
respiratory tract (Antman and Chang, 2000; Colman and Blackbourn, 2008).  With the AIDS 
pandemic, KS incidence has increased in sub-equatorial African countries and is the most 
frequently detected tumour in AIDS patients (Damania, 2007). Unlike KS, only half of MCD 
cases are associated with KSHV; MCD is a follicular hyperplasia of lymphoid tissue and, in its 
more aggressive form, has been described as a disease resulting from B-cell hyperproliferation 
(Menezes et al. 2007). Similarly, PEL is a B-cell lymphoma arising in immunodeficient patients, 
 -2- 
characterised by lymphomatous effusions. The associated cancers reflect KSHV tropism, and 
both MCD and PEL have a poor prognosis, and are yet to have a successful treatment formalised 
(Bower, 2010). Thus, KSHV provides an attractive target in the search for cancer therapies, and 
the role of KSHV in the induction and development of malignancies is an area of intense 
research. Not only will this, but knowledge of viral mechanisms of proliferation, persistence, 
immune modulation and oncogenesis benefits the fields of virology, oncology and cell biology. 
Understanding viral oncogenesis and immune modulation can be extrapolated to other viruses, 
and tumour virus interactions with cell machinery highlights important cellular oncoproteins and 
tumour suppressors. 
As a herpesvirus, KSHV has evolved to establish persistent infection in the host and therefore 
exist in equilibrium with the host immune defences. KSHV alone is not enough to transform 
endothelial cells, but is a major contributor once the equilibrium is disturbed. For example, in 
immunodeficient situations immune control of the virus is insufficient, allowing reactivation of 
the virus and disease manifestation (de Oliveira, 2007). Thus, the initial detection and production 
of an immune response against the virus is an important factor in viral suppression and 
dissemination. 
1.2 KSHV Evasion of the Immune System 
As previously mentioned, KSHV, like other herpesviruses, is able to evade and subvert host cell 
machinery in order to promote viral survival and growth. In order to establish a chronic 
infection, it is essential to avoid host detection and set up a latent state. Consequently, more than 
22 of the 86 genes encoded by the KSHV genome are thought to act upon human adaptive and 
innate immune mechanisms, in order to facilitate viral persistence (see Rezaee et al. 2006) (Figure 
1). KSHV immunomodulatory proteins are known to act upon the host interferon response, 
complement and cytokine secretion in order to dampen initial responses against the virus and 
prevent recruitment of immune cells and further immune responses (see Arresté and Blackbourn 
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2009). For example, the virally encoded vIRFs and ORF45 proteins inhibit the host interferon 
response (Zhu et al. 2002), and the KSHV ORF4-encoded complement control protein (KCP) 
inhibits complement-mediated lysis of infected cells (Spiller et al. 2003). KSHV proteins also act 
upon adaptive host immune responses. Examples include the viral E3 ubiquitin ligases MIR1 and 
MIR2, which target MHC1, enhancing its endocytosis and thus inhibiting viral antigen 
presentation (Coscoy et al. 2001). Furthermore, by encoding chemokines that bind Th1 receptors 
but do not incur intracellular signalling, KSHV prevents Th1 chemotaxis to the infected area and 
skews the ensuing cell-mediated immune response towards a Th2 effector cell focus, shifting the 
immune response to an antibody-mediated response (Stine et al. 2000). There are more immune 
modulatory functions of KSHV than can be comprehensively covered here, and together 
immune evasion proteins advance viral persistence. These same viral mechanisms contribute to 
the deregulated cellular proliferation and apoptotic resistance that leads to the oncogenic 
transformation of a host cell.  Evasion of the host immune response allows KSHV to set up a 
persistent state and thus expression of genes that promote cell existence. Such viral proteins 
include latency-associated nuclear antigen (LANA), which increases infected cell life span by 
interaction with hTERT (Verma et al. 2004), v-cyclin which mimics cellular D-cyclin (Chang et al. 
1996) and virally encoded miRNAs (Cai et al. 2005), all of which contribute to latency and 
extended cell lifespan (see Mesri et al. 2010). Such evasion of immune surveillance and promotion 
of cellular proliferation can contribute to mutational accumulation and development of the 
characteristic hallmarks of cancer (Hanahan and Weinberg, 2000). 
As such a large proportion of the KSHV genome is dedicated to immune evasion, it is logical 
that TLRs, as one class of innate sentinels of the immune response, are targets of interaction and 
manipulation by KSHV. Activation of TLRs may initiate antiviral responses, but these pathways 
may also aid viral replication and propagation. Activation of the transcription factor NFκB leads 
to the transcription of pro-inflammatory cytokines such as interleukin-6 and -8, which induce an 
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antiviral state in neighbouring cells, and an immune response aimed at eliminating virus infection 
(Takeuchi and Akira, 2009). At the same time, NFκB inhibits the activation of viral lytic 
promoters and proinflammatory cytokine production may aid KSHV by recruiting cells for 
further infection (Brown et al. 2003). KSHV is implicated in the activation of pDCs via TLR9 
(West et al. 2011), thus promoting an inflammatory state and bringing KSHV tropic cells into 
close contact for infection. It is important for KSHV to avoid the initial detection and signalling 
cascades that would cause an antiviral state, but to balance this with allowing the activity of 
NFκB to suppress lytic replication that would be damaging to the establishment of long-term 
infection. 
1.3 Toll-like receptors (TLRs) 
Elimination or control of pathogen replication requires interaction between the innate and 
adaptive arms of the immune response. TLRs occupy the central position in this system, acting as 
the first response to recognise pathogen-associated molecular patterns (PAMPs). These innate 
receptors detect pathogen-associated ligands and alert the appropriate immune cells and 
subsequent responses. Currently, 10 TLRs are known in humans, designated TLR 1 to TLR 10 
(Takeuchi and Akira, 2010), which form homo- or hetero- dimeric receptors at the cell surface or 
endosomally (Table 1). The TLR family of receptors are type 1 transmembrane glycoproteins 
with an immunoglobulin-like extracellular domain and a Toll/interleukin-1 receptor (TIR) 
intracellular domain, through which downstream signalling cascades are initiated (Bowie and 
O’Neill 2000) (Figure 2). The conserved extracellular domain in all TLRs contains between 21 
and 25 leucine-rich repeats (LRRs), which recognise and bind cognate PAMPs (Akira et al. 2006). 
Once activated, signalling cascades operate via either the MyD88-dependent or the MyD88 
independent pathways to activate the transcription factor NFκB, which directs the transcription 
of proinflammatory cytokines (see Akira and Takeda, 2004) (Figure 2). Various viral components, 
such as surface glycoproteins and nucleic acids, are recognised by TLRs, typically leading to a 
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type 1 interferon response, and the induction of an antiviral state in infected and surrounding 
cells (Akira and Takeda, 2004). The type 1 interferon response is a prominent host virus control 
mechanism, and it is already known that KSHV encodes several genes to counteract the innate 
interferon system. For example, cellular interferon response factor 7 (IRF-7) is targeted for 
caspase-mediated degradation by virally-encoded RTA (Arresté et al. 2009, Yu et al. 2005), and 
viral protein LANA is able to block interferon activation via cellular IRF-3 (Cloutier et al. 2010). 
KSHV encodes four interferon regulatory factor (IRF) homologues (vIRF1, vIRF2, and vIRF3), 
which are able to downregulate the production of interferons by acting dominantly over cellular 
IRFs on regulatory factors and elements (Fuld et al. 2006, Bisson et al. 2009). Thus, we 
hypothesise that KSHV is likely to encode proteins to counteract the interferon response induced 
by TLRs, which would otherwise be detrimental to establishment of KSHV infection. 
TLRs are known to be central to viral detection, and are found on cells central to the initial 
detection of pathogens and influencing the resulting direction of the immune response. These 
cells include plasmacytoid dendritic cells (pDCs), which produce large amounts of interferon in 
response to viral infection (Krug et al. 2004). There is specific evidence for TLR-mediated 
detection of the family Herpesviridae by human TLRs (Table 1). For example, TLR 2 is activated 
by human cytomegalovirus (HCMV) stimulation of peripheral blood mononuclear cells (PBMC) 
(Compton et al. 2003), and has been shown to be activated by EBV in human monocytes 
(Gaudreault et al. 2007). The endosomal receptor TLR 3 detects the viral dsRNA of 
herpesviruses, including the non-coding Epstein-Barr virus (EBV) transcripts and dsRNA 
intermediates produced during KSHV replication (West and Damania, 2008). Similarly, TLR 9 is 
activated by DNA sequences containing unmethylated deoxy-CpGs, motifs abundant in HSV-1, 
HSV-2 and murine cytomegalovirus (MCMV) (Hochrein et al. 2004, Krug et al. 2004). Further 
complexity is evident through cooperation between different TLRs in viral detection is likely; 
TLR 2 and 9 have both been shown in mouse models to be required together for HSV-2 
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detection (Sorensen et al. 2008), TLR 3 and 9 important in resistance to MCMV (Tabeta et al. 
2004), and TLR 7 and 9 are highly expressed on pDCs and are both involved in the detection of 
EBV ds and ss RNA by these cells in vitro (Quan et al. 2010). 
The importance of TLRs in immune surveillance is reflected in the number and variety of viral 
evasion strategies employed to evade them. More specifically, downregulation of TLRs has 
already been seen in other herpesviruses. For example, TLR 9 expression is downregulated by 
EBV at both an mRNA and a protein level (van Gent et al. 2010), and EBV LMP-1 protein acts 
upon the TLR 9 promoter to downregulate expression (Fathallah et al. 2010).  EBV also 
negatively affects TLR 2 transcription and protein functionality (Fathallah et al. 2010) and HSV-1 
downregulates TLR 2 mediates inflammatory responses (van Lint et al. 2010).  Converesly, KSHV 
is known to upregulate TLR 3 pathway components in human monocytes, leading to 
transcription of proinflammatory cytokine genes through NFκB activation (West and Damania, 
2008). Thus viruses are able to both positively and negatively modulate TLR function at both the 
mRNA and protein level. It is highly likely that KSHV utilises mechanisms to evade immune 
detection by TLRs and their anti-viral consequences, and the study of such mechanisms will 
provide and exciting insight into the establishment and control of infection by the host. 
With such precedence seen in the Herpesviridae family, and some suggestion of KSHV-TLR 
interactions, it is reasonable to hypothesise that KSHV will influence TLR levels, acting either at 
a transcriptional, translational and/or post-transcriptional level. We hypothesise that one or more 
of the human TLRs is responsible for detecting KSHV infection and providing some resistance 
to infection, and that KSHV targets relevant TLRs by negatively regulating mRNA levels. Having 
obtained stable cell lines expressing each of the nine human TLRs individually, and in order to 
gauge the effect of KSHV infection on TLR mRNA levels, we aim to determine whether KSHV 
infection is sensitive to the expression of individual TLRs, and to identify any changes in 
individual TLR gene transcription by quantifying their mRNA levels. 
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1.4 Hypothesis, Aims and Objectives 
We hypothesise that one or more human TLR is responsible for detecting KSHV infection and 
providing some resistance. Therefore, KSHV may target relevant TLRs by negatively regulating 
their mRNA levels. We aim to determine whether KSHV infection is sensitive to the expression 
of individual TLRs, and to determine whether KSHV infection affects the mRNA levels of 
particular TLRs. We used cell lines expressing individual human TLRs, subject them to infection 
by KSHV and analysed by flow cytometry and reverse transcription (RT) PCR, and RT semi-
quantitative PCR (sqPCR). Throughout the experiment a non-transfected control cell line was 
treated in parallel. In the PCR experiments, infected and uninfected cells were compared. 
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2. Methods 
Unless otherwise stated, materials and chemicals were obtained from commercial sources. 
2.1 Cells and Cell culture 
Human embryonic kidney (HEK) 293 cell lines ectopically expressing individual human TLRs 
(TLRs 3, 4, 5, 7, 8 and 9 as homodimers and TLRs 1/2, 2/CD14 and 2/6 heterodimers) were 
obtained from collaborators (Dr M. Ressing, Department of Medical Microbiology, University 
Medical Center Utrecht). The expression vectors conferred antibiotic resistance (van Gent et al. 
2010). These cell lines were maintained alongside non-transfected HEK-293 control cells taken 
from an already growing source within the Blackbourn lab. Cells were grown within flasks 
containing media comprising Dulbecco’s modified eagle media (DMEM, Gibco) supplemented 
with foetal bovine serum (FBS, Gibco, 10% v/v), L-glutamine (Sigma, 2mM), penicillin (Sigma, 
200mM) and streptomycin (Sigma, 67mM). This supplemented DMEM cell culture media is 
referred to as complete DMEM throughout. Cells were cultured by incubation at 37oC and 5% 
CO2, in a humidified environment. Human TLR-expressing cell lines were cultured in media 
containing selective antibiotics as recommended (Table 2). Non-transfected HEK-293 control 
cells were unable to grow in antibiotic-containing media, giving reassurance that the transfected 
cells were selected for. Cells underwent at least three passages in selective medium before use in 
experiments.  
Table 1: Selective antibiotics used to isolate and culture TLR-expressing cell lines 
Antibiotic Final concentration (in 
complete DMEM)  
Selected HEK-293 cell lines expressing 
ectopic TLR 
Blasticidin 10 μg/ml 3, 5, 6, 7 and 8  
G418 700 μg/ml 9 
Puromycin 10 μg/ml 2 and 4 
2.2 KSHV infection of cells and flow cytometry 
The rKSHV.219 strain used in these studies expresses green fluorescent protein (GFP) from the 
EF-1α promoter during latent infection and red fluorescent protein (RFP) from the PAN 
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promoter during lytic infection (Vieira and O’Hearn, 2004). Virus was prepared as described 
previously (Viera and O’Hearn, 2004), and infectious units (IU) of rKSHV.219 determined by 
titre of virus in cell-free medium on HEK-293 cells, counting GFP-positive cells 2 days post-
infection. Virus was resuspended in epithelial basal media-2 (EMB2, Gibco).  
For infection experiments, HEK-293 cells were isolated from main stocks and seeded at 2x105 
cells per ml in a 96 well plate, and incubated overnight in the appropriate media before 
stimulation with purified rKSHV.219 at multiplicities of infection (MOIs) of 10, 5, 1, and 0.1. 
MOI is a measure of IUs per cell, and allows comparability between different experiments. The 
plate of virus plus cells was then centrifuged (450 x g, 30 min, room temperature) and incubated 
for an hour. Virus was then removed, the cells washed with media and incubated for 48 hours. 
Cells were removed by trypsinisation, fixed in 1% paraformaldehyde (PFA) and transferred to 
cytometry tubes for quantification of GFP expression, as a measure of the extent of rKSHV.219 
infection. A Coulter EPICS XL-MCL flow cytometer was used to analyse GFP levels (Beckman 
Coulter, UK) and the FlowJo programme (Treestar Inc.) used to analyse the resulting data, gating 
first on live cells, and then on GFP-expressing cells. Different gates were used for each cell line, 
due to the differences in morphology, but the same gate was used within a cell line, applied to the 
different MOIs.  
For RNA analysis, cells plated at 2x105 cells per ml in a 6 well plate were infected the next day 
with purified rKSHV.219 at an MOI of 5, using the same method as described for the 96 well 
plates. Corresponding wells were plated with cells in parallel and treated with EMB2 medium 
rather than virus for analysis of non-infected cells as a control. Latent infection was confirmed by 
observation of GFP fluorescence under a fluorescent microscope. Cells were harvested by 
trypsinisation, pelleted and snap-frozen in liquid nitrogen and stored at -80oC for further use. 
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2.3 RNA isolation, cDNA transcription and PCR 
From each TLR-expressing cell line and a HEK-293 control cell line, approximately 5x106 cells 
were isolated, pelleted and snap frozen. The total cell RNA was extracted from the thawed pellet 
using an RNeasy Mini Kit (Qiagen), according to the manufacturer’s instructions, and quantified 
by spectrophotometry.  
RNA was treated with DNase (Promega) as recommended by the manufacturer, in order to 
remove any genomic DNA that could be amplified by PCR and give false positive results. Two 
hundred and fifty nanograms of DNase-treated RNA was used for complementary DNA 
(cDNA) transcription using random hexodeoxynucleotide primers (100mM, Invitrogen) and the 
Moloney murine leukemia virus reverse transcriptase (MLV RT, Promega) in the presence of 
RNase inhibitor (Promega) and nucleotides (10mM, Promega). MLV RT synthesises a 
complementary strand of DNA from a template in the presence of random primers. Before 
addition of enzyme, the reaction was heated to 65oC for 5 min and chilled on ice quickly, in order 
to denature any RNA secondary structure that would prevent efficient primer annealing. 
Polymerase and RNase inhibitor was then added and the reaction incubated at 37oC for 50 min to 
allow sufficient primer elongation. The enzyme was inactivated by heating to 70oC for 15 min. To 
confirm the absence of genomic DNA in the later stages of the experiment, parallel reactions 
were performed without the reverse transcriptase enzyme.  
Resulting cDNA was used as a template for amplification in a PCR using GoTaq polymerase 
(Invitrogen), 2μl of cDNA from the first strand reaction and specific primers (Table 3) to amplify 
TLR genes, in seperate reaction volumes (50μl). Amplification of the housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a positive control for each 
cell line, alongside a reaction incorporating DNA extracted from a HEK-293 cell line where 
GAPDH is present in the genome. DNA fragments of expected length were visualized by 1% 
agarose gel electrophoresis and ethidium bromide staining, using a bromophenol blue loading 
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buffer dye and tris-acetate-EDTA (TAE) electrophoresis buffer, loading 10μl of sample against 
1μg of 100bp DNA ladder (Invitrogen). 
 Table 2: Primer sequences for the detection of TLR expression 
mRNA 
target 
Forward 5’-3’ Reverse 5’-3’ Amplified 
Fragment 
size (kbp) 
TLR 1/2 AAAAGAAGACCCTGAGGGCC TCTGAAGTCCAGCTGACCCT 340 
TLR 
2/CD14 
AACCCTAGGGGAAACATCTCT GGAATATGCAGCCTCCGGAT 549 
TLR 3 AAATTGGGCAAGAACTCACAGG GTGTTTCCAGAGCCGTGCTAA 320 
TLR 4 TACAAAATCCCCGACAACCTC AGCCACCAGCTTCTGTAAACT 264 
TLR 5 TGCATTAAGGGGACTAAGCCTC AAAAGGGAGAACTTTAGGGACT 351 
TLR 6/2 TTGACAGTTTTGAGACTTTCCC TGAACCTCTGGTGAGTTCTG 516 
TLR 7 TCCAGTGTCTAAAGAACCTGG TGGTATATATACCACACATCCC 532 
TLR 8 TAATAGGCTCAAGCACATCCC TCCCAGTAAAACAAATGGTGAG 621 
TLR 9 GTGCCCCACTTCTCCATG GGCACAGTCATGATGTTGTTG 260/212 
GAPDH 
(a) 
CCCACTCCTCCACCTTTGAC CCTCTTGTGCCTTTGCTGGG 178 
GAPDH 
(b) 
GAGCCACATCGCTCAGACAC GCTTCCGTTCTCAGCCTTG 220 
GAPDH primers were used to amplify the housekeeping genes, and act as a standard in sqPCR. 
Where the PCR reaction was paused at 20, 25 and 33 cycles and 10ul aliquots removed from each 
reaction and stored at 4oC. All samples were analysed together by agarose gel electrophoresis. 
TLRs 1/2, 2/CD16 and 6/2 work as heterodimers involving one of each of the named receptor. 
The first number is the one that will be used to refer to the receptor as a whole within our 
experiments. Annealing temperature of 55oC was used for all primer pairs. 
2.4 Semi-quantitative PCR (sqPCR) 
Unless stated otherwise, cDNA from infected and uninfected cell samples were treated in exactly 
the same way. KSHV infected cell samples from the infection step were subject to mRNA 
extraction and cDNA transcription carried out as described above. cDNA was specifically 
amplified with relevant TLR primers and primers for GAPDH, by polymerase chain reaction 
(PCR). During the reaction, 10μl aliquots from these samples were taken at 20, 25 and 35 cycles, 
by stopping the machine at the relevant number of cycles and transferring aliquots for storage at 
4oC. All samples were visualised together on a 1% agarose gel with ethidium bromide staining, as 
described above. Relative brightness of the amplified bands was compared visually between 
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infected and non-infected cDNA from the same cell line, using GAPDH brightness as a loading 
volume control. 
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3. Results 
In order to investigate whether ectopic expression of individual TLRs affected the efficacy of 
rKSHV.219 infection, we infected HEK-293 cells expressing individual human TLRs with this 
virus at a range of MOIs. The extent of infection was quantified by measuring GFP expression 
by flow cytometry, using a non-transfected HEK-293 control for comparison. This strategy 
revealed whether rKSHV.219 infection was sensitive to the expression of any TLR, and the 
results translate to wild type virus. Extraction of mRNA and subsequent analysis of infected and 
uninfected samples from each cell line confirmed TLR expression and allowed a comparison of 
mRNA levels between infected and uninfected cells.  Thus we could suggest whether KSHV 
infection affects the levels of TLR mRNA within this cell system. 
3.1 HEK-293 cell lines express the transfected human TLRs 
To confirm TLR expression, each cell line was subjected to RNA analysis via RT-PCR.  TLR 
mRNA transcribed to cDNA and amplified by PCR, using specific primers to amplify TLR 
cDNA. In parallel, untransfected control cells were subject to RT-PCR in order to test whether 
the HEK-293 cell line naturally expresses any TLR. Visualisation of amplified fragments on an 
agarose gel showed that each cell line expressed the expected individual TLRs (Figure 3). Bands 
were seen at the expected size for each TLR and control cDNA prepared in the absence of 
reverse transcriptase showed no bands of amplified TLR cDNA (Figure 3). The absence of TLR 
DNA amplification in samples where no reverse transcriptase was present suggests that there was 
no contaminating cDNA, and that bands corresponded to the presence of TLR mRNA in the 
cultured cells. The absence of bands in control HEK-293 cell samples indicate that the cells do 
not express any TLRs at a level detectable by ethidium bromide (Figure 3).  Individual amplified 
fragment amounts vary, for example TLR 3 appears to have amplified to a greater amount than 
TLR 2, and the band for TLR 9 is very faint (Figure 3, top and bottom panels). However, PCR 
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amplification is sensitive to conditions and cycles, and these differences are attributable to the 
variations in primer pair length and GC content as well as gel loading. This information was 
enough to give us confidence that the provided cell lines were expressing the relevant receptors 
and could be subject to further experiments, alongside the current control. It is important to note 
that the control untransfected HEK-293 cell line did not show expression of any tested TLR 
(Figure 3), and thus we can confidently attribute differences in KSHV infection efficiency to 
ectopic TLR expression. 
3.2 Cell lines expressing human TLRs are infected by KSHV at different efficiencies 
Using flow cytometry, we investigated whether the ectopic expression of a human TLR in a 
HEK-293 cell line was responsible for detecting rKSHV.219 infection and whether such 
expression affected infection efficiency. This model cell system mimics cellular expression of 
TLRs and their effect on initial infection of wild type KSHV. Infection of cell lines expressing 
each of the human TLRs 1-9 separately, at a range of MOIs, allowed the determination of 
whether KSHV infection is sensitive to TLR expression. Infection was quantified by flow 
cytometry, detecting the GFP expression induced by rKSHV.219 infection. Initial observations 
under a fluorescence microscope showed successful infection and latent expression of the virus, 
seen as green fluorescence emission (Figure 4).  Expression of GFP rather than RFP indicates a 
latent infection (Viera and O’Hearn, 2004). Infection of the different cell lines is visibly 
comparable at the same MOI, but more accurately measured by flow cytometry. All cell lines 
showed GFP expression upon infection, although the proportion of GFP-expressing cells 
appears to vary. Figure 4 shows that cell lines expressing TLRs 4 and 9 appear to be less infected 
than the other cell lines at comparable MOIs. Cell lines expressing TLR 4 and 9 show GFP 
expression in approximately 30-40% of cells at MOI 5, whereas the TLR 2, 6 and 5 expressing 
cells show approximately 50-60% of cells infected, and TLR 1 and 3 expressing cells appear to 
have the highest infection, with approximately 70-80% of cells expressing GFP at the same MOI.  
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Cell densities vary, due to the difference in growth rates between cell lines (Figure 4). The higher 
MOIs, 10 and 5, show visibly higher levels of infection as higher GFP density in these images, 
compared to lower MOIs, 1 and 0.1 (Figure 4). In the case of TLR 1, 2, 4, 7, 8 and 9 expressing 
cells, infection at an MOI of 0.1 showed no visible GFP expression (Figure 4), and is reinforced 
by flow cytometry data (Figure 5, panel A). As was expected, varying MOIs produced different 
extents of infection; a higher MOI gave a higher density of GFP-expressing cells (Figure 4). 
Morphology of the cell lines differed subtly compared to control, which was observable via the 
light microscope (Figure 4) or when analysing by flow cytometry. TLR 7 and 8 expressing cells 
were less adherent and more rounded in shape compared to the control HEK-293 cells, which 
have a more spikey appearance (Figure 4). Differences in morphology led to the need for 
different gating on live cells during the flow cytometry, although the gates were maintained 
within a cell line for quantification of GFP at different MOIs. 
Flow cytometry data shows infection of cells at MOIs 0.1 and 1 gave less consistent results than 
higher MOIs (5 and 10) (Figure 5 panel A). Inconsistency was seen both between individual 
experiments and within each data set; values at these MOIs are extremely variable. It is likely that 
this variability is due to the small amounts of virus involved at the low MOIs. With smaller 
volumes, any discrepancy in volume has a bigger impact on amount of virus (Figure 4 panel A), 
and thus creates a large amount of deviation between values. The differences between the cell 
lines and control were not analysed in depth at low levels of infection, and data gained from 
MOIs of 5 and 10 form the focus of conclusions drawn. 
Efficiency of infection of HEK-293 at MOIs of 5 and 10 appeared to be unaffected by the 
ectopic expression of TLRs 1, 6, 7, 8 and 9 compared to control (Figure 5 panel B). These data 
suggest that KSHV infection is not sensitive to the expression of these receptors. 
The flow cytometry data indicates that KSHV infection is sensitive to the expression of TLRs 2, 
3, 4, and 5, with TLRs 2 and 4 having the most effect (Figure 5 panel C). HEK-293 cell lines 
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expressing these receptors show lower infection efficiency than control cells, these data are 
consistent at the MOIs of 5 and 10 (Figure 5 panel C).  Both TLR 2 and 4 have lower infection 
efficiencies than control cells by a factor of approximately 50% whereas KSHV is less sensitive to 
the expression of TLRs 3 and 5, with infection efficiency of 25% less than the average control 
cell infection efficiency (Figure 5, panel C). 
3.3 Levels of cellular TLR mRNA levels can be affected by KSHV infection 
RT sqPCR analysis was applied to cells expressing TLRs 3, 4, 5 and 7, comparing infected and 
uninfected samples of the same passage. Samples were taken from the paused PCR at 20, 25 and 
33 cycles and all were visualised by agarose gel electrophoresis. In the samples analysed, amplified 
bands of DNA taken at 33 cycles were all at a comparable brightness, as expected, due to the 
reaction reaching a plateau as reagents become limiting. Samples taken at the earlier cycles of 20 
and 25 are predicted to be within the logarithmic expansion phase, and thus should give an 
indication of any difference in sample cDNA template levels when compared to each other, 
assuming that housekeeping gene (GAPDH) amplification is equivalent. In most cases, faint or 
no bands were visible at 20 cycles, and thus most of the comparison occurs at 25 cycles. 
When analysed by sqPCR, both infected and uninfected cell lines expressing TLR 3 showed 
unvarying levels of TLR 3 mRNA at 33 cycles, the only stage at which template amplification was 
detected. Indicating that TLR 3 mRNA levels are not affected by KSHV infection (Figure 6). 
Bands were barely visible at 20 cycles, and not useful to draw conclusions from, and the 
brightness of bands compared between infected and non-infected cells was seen to be almost 
equal at 25 cycles and 33 cycles.  
sqPCR of the cell line expressing TLR 4 does not appear to show a difference in the amount of 
TLR template between infected and non-infected cell samples (Figure 7). Amplified cDNA from 
uninfected cells show a marginally brighter band than the equivalent from the infected cell 
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samples, but the GAPDH brightness decreases, suggesting that KSHV infection does not affect 
TLR 4 mRNA. 
From RT sqPCR analysis, TLR 5 mRNA levels appear to be unchanged in TLR 5 expressing 293 
cells before and after infection (Figure 8). Levels of both TLR 5 and GAPDH at 33 cycles are 
comparable, but are not at 25 cycles. Because GAPDH levels are not comparable, the difference 
between TLR 5 fragment brightness between infected and uninfected samples is slight and would 
be better analysed by a more quantitative method. 
The most obvious change in mRNA levels between KSHV positive and negative samples was 
seen in the analysis of TLR 7. Amplified cDNA from TLR 7 expressing cells is absent in infected 
samples (Figure 9). Analysis by sqPCR showed no detectable expression of TLR 7 following 
KSHV infection. No bands are visible at either 25 or 35 cycles, compared to equivalently treated, 
uninfected cells expressing TLR 7 (Figure 9). The difference seen between infected and 
uninfected samples is considerable and merits further investigation. 
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4. Discussion 
TLR detection is the ‘first-line’ of defence in immunity, and thus the receptor family are an 
important group in terms of viral evasion; avoiding initial detection by TLRs promotes virus 
infection and dissemination. Thus, one can assume that KSHV employs mechanisms to interact 
with and modulate any of the TLRs that affect its ability to infect cells and set up persistence. 
These experiments give an overview of the changes that occur in TLR mRNA when infected 
with recombinant KSHV, and form a solid basis for further verification and investigation.  
The receptors TLR 1, 6, 8 and 9 have been implicated in herpesvirus detection. TLR 1/2 
heterodimers expressed on the cell surface of pDCs are activated by HCMV glycoproteins 
(Boehme et al. 2006). TLR 8 has been implicated in KSHV reactivation from latency (West et al. 
2011) and TLR 9 signalling is activated by KSHV infection of pDCs, despite mRNA levels being 
unaffected by KSHV infection (Lagos et al. 2008). However, we saw no effect of the expression 
of these TLRs on HEK-293 cells on KSHV infection efficiency. It is likely that the interactions 
and effects of KSHV and TLRs is cell-specific and that these differences are attributable to the 
variance in cell type. 
TLR 2 is prominent in the detection of hydrophobic PAMPs, and is expressed on DCs, 
monocytes and macrophages (Table 1), primary responders to KSHV infection (Krug et al. 2004). 
There are examples of herpesviruses stimulating proinflammatory cytokine production via 
stimulation of TLR 2 (Table 1). Notably, HCMV activates inflammatory response via 
TLR2/CD14 heterodimer on human monocytes (Compton et al. 2003), and EBV induces 
monocyte chemotactic protein-1 (MCP1) production via stimulation of TLR 2 on primary 
monocytes (Gaudreault et al. 2007). Our data shows that ectopic TLR 2 expression by HEK-293 
cells reduces susceptibility to KSHV infection. The mechanism of this is unknown, and whether 
KSHV affects TLR 2 mRNA levels is also unknown. It is likely that the receptor recognises viral 
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glycoproteins, as it does the glycoproteins of HCMV (Boehme et al. 2006). As TLR 2 is expressed 
on the surface of the host cell, detection of viral glycoproteins is likely to occur whilst virus is still 
outside of the cell, during initial infection. The epitope detected by TLR 2, and which stage of 
infection detection occurs is something that can be deduced structurally or investigated using 
site-direct mutagenesis. In this system the TLR 2 gene has been transduced alongside CD14, 
allowing the two to act together as a heterodimer. Transfection of TLR 2 with other known 
molecular partners, such as CD36 and RP105 (Kumar et al. 2009), would highlight the specificity 
of TLR 2-KSHV interactions. On this basis, the effect of TLR 2 expression on KSHV infection 
warrants further investigation. 
Dendritic cells and B cells are known to express TLR 3, which detects pathogen-associated 
double-stranded and single stranded RNA (Alexopoulou et al. 2001) (Table 1). KSHV sets up a 
latent infection in B cells (Dupin et al. 1999), indicating that TLR 3 may be especially relevant to 
viral detection. Our evidence suggests that TLR 3 expression causes cells to be slightly resistant 
to infection by KSHV; expression of TLR 3 is not affected by KSHV infection but KSHV 
infection is sensitive to ectopic expression of TLR 3. It is possible that encounter of ligand and 
TLR occurs following endocytic entry of the virus into the cell, not a conventional method of 
viral entry, but one seen in some cell types, including B cells (Akula et al. 2003). To become 
activated by the virus, TLR 3 may detect packaged RNA within the KSHV virion, exposed to the 
receptor during fusion-mediated entry of the virus within the endosome (West and Damania, 
2008). With respect to other herpesviruses, activation of TLR 3 is detrimental to HSV-1 latent 
infection of neurones (Zhou et al. 2009). However, KSHV infection has been shown to 
upregulate TLR 3 at a transcriptional level in monocytes, a cell type that the virus is able to infect 
(West and Damania, 2008). It has been suggested that TRIF, a signalling protein downstream of 
activated TLR 3 and 4 signalling, is degraded by KSHV (Ahmed et al. 2011). By acting to prevent 
intracellular signalling, KSHV prevents an antiviral inflammatory response that could be caused 
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by TLR 3 upregulation. The sensitivity to TLR 3 expression that we see may be overcome once 
the virus has infected host cells. The position of TLR 3 in our model system may not resemble 
the in vivo situation, and experiments in naturally TLR 3 expressing cell lines could yield 
contrasting results.  
TLR 4 is involved in viral glycoprotein and lipopolysacharide (LPS) detection and is expressed 
endosomally by Monocytes/macrophages, DCs, mast cells and intestinal epithelial cells (Table 1). 
Our results disagree with previous data that show that infection of lymphatic endothelial cells 
with KSHV rapidly suppresses TLR 4 mRNA and protein levels (Lagos et al. 2008), and also with 
data that suggests that lack of TLR 4 expression renders cells more susceptible to KSHV 
infection (Lagos et al. 2008). These differences are attributable to the differences in the model 
systems used and altogether suggest a role for TLR 4 in innate immunity against KSHV, which 
needs to be characterised fully. It is feasible that TLR 4 recognises herpesvirus glycoproteins, as it 
does the glycoprotein F of respiratory syncytia virus (RSV) (Kurt-Jones et al. 2000). Like TLR 3, it 
is likely that KSHV has mechanisms to overcome the antiviral response once a cell is infected. 
TLR 5 is known to detect bacterial flagellin (Hayashi et al. 2001), and thus it is unclear why its 
expression would affect KSHV infection. However, most TLRs have a range of ligands (Akira 
and Takeda, 2004), and we are open to the possibility that there are undiscovered ligands for all 
of the TLRs. In this case, TLR 5 may well interact with lipids present in the virion envelope. The 
structure of TLR 5 may have regions of homology with the other cell-surface expressed TLRs, 
and could loosely interact with a common viral epitope to become activated. Therefore, 
expression of TLR 5 renders KSHV sensitive to cell infection, due to an unspecific interaction 
that causes the virus the difficulty in entering a target cell that we see in our flow cytometry data. 
This is speculation, and elucidation of the mechanism behind this result requires further 
exploration. 
 -21- 
Like TLR 3, TLR 7 recognises viral ssRNA (Heil et al. 2004). KSHV has been suggested to 
activate pDCs via TLR 7 and TLR 9, leading to interferon production (West et al. 2011).  TLR 7 
is also known to interact with the herpesviruses Varicella-Zoster virus (VZV) (Martin et al. 2007) 
and EBV RNA and DNA is known to stimulate pDCs to produce interferon, via interaction with 
TLRs 7 and 9 (Quan et al. 2010). Here we have shown a large decrease in TLR 7 mRNA in 
KSHV infected cells, compared to uninfected, despite no observable KSHV sensitivity to TLR 7 
expression seen in flow cytometry experiments. Reduction of TLR 7 at an mRNA level 
presumably decreases the amount of protein and aids KSHV evasion of innate immune 
activation. The lack of sensitivity to infection of TLR 7 expressing cells may be due to KSHV 
reducing TLR 7 protein levels relatively quickly after infection, in order that a TLR 7–activated 
anti-viral response is not triggered by KSHV. The mechanism of TLR 7 reduction may has arisen 
as a mechanism by of KSHV to overcome TLR 7 activated signalling that was originally 
detrimental to the life cycle of KSHV. KSHV has co-evolved with the host to evade this 
particular mechanism of immune defence. It may also be due to the difference in receptor 
localisation in our model. In vivo TLR 7 is expressed endosomally, and thus KSHV would only 
come into contact with the receptor post-infection. During viral infection, viral ssRNA may 
reach the endosome via receptor-mediated uptake of viral particles or by fusion of virus and cell 
membranes. Exposure of viral nucleic acids, such as RNAs packaged within the mature virion, 
may occur within the endosome during primary infection (Bechtel et al. 2005). Such RNAs ensure 
quick transcription of viral genes after entry, but could endanger the virus by binding to TLR 7, 
leading to an immediate and strong induction of type 1 IFN (West and Damania, 2008). 
Therefore, it is sensible that the virus has evolved mechanisms of evading an anti-viral interferon 
response via downregulation of a receptor that would begin the signalling cascade. The speed of 
TLR 7 suppression following KSHV infection in these experiments suggests that a viral structural 
protein is involved in the downregulation mechanism. Both HSV-1 and -2 utilise a similar 
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mechanisms, where the VP16 tegument protein acts to transactivate genes favourable for viral 
immediate early gene transcription (Campbell et al. 1984). As herpesviruses, many of the 
mechanisms of immune evasion are comparable. KSHV protein RTA is present in infectious 
virions, and is known to target cellular proteins for downregulation (Bechtel et al. 2005b, Yu et al. 
2005). It is possible that the transactivation properties of RTA allow downregulation of TLR 7 at 
a transcriptional level, thus reducing mRNA levels relatively soon after entry into the host cell.  
Type one interferons are important in the control of viral infections, including KSHV. Counter-
action of TLR-induced interferon responses are required for KSHV survival in vivo. Furthermore, 
interaction with TLRs allows KSHV to capitalise on the host innate immune response; without 
such a response to KSHV infection, the virus could prove fatal for the host. There is evidence 
that pDCs play a beneficial role in herpesvirus infection (Krug et al. 2004). Thus, activation of the 
host innate immune response against KSHV not only restrains viral replication and 
dissemination, but provides selective pressure on the virus to enter a latent state. Consequently, 
the virus is able to evade the adaptive immune responses that are activated by a successful innate 
immune response. Virus and host are in a constant, dynamic equilibrium between infection and 
immunity. 
This model cell system emulates TLR expression and KSHV interaction with the receptors at the 
cell surface, as well as with TLR gene expression. TLRs 1, 2, 4, 5 and 6 are expressed on the cell 
surface in the in vivo situation (Table 1), as they are in our model system. However, TLRs are 
expressed in vivo on a variety of cell types, including monocytes, epithelial cells and dendritic cells 
(Table 1) and the HEK-293 cells do not normally express TLRs. In vivo expression localisation of 
TLRs is not necessarily represented in this experiment. For example, TLRs 3, 7, 8 and 9 are 
expressed endosomally (Table 1), but it is likely that they are cell-surface expressed in our model 
system. Thus localisation of TLRs in the model may not exactly mimic an in vivo situation, and 
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virus interactions may also therefore differ. It would be useful to confirm localisation of the 
receptors by immunofluorescence in future investigations using this model. 
Selection-containing medium killed control HEK-293 cells, indicating that cell survival in 
selection media is due to the expression of the correct TLR gene transduced into cells alongside 
antibiotic resistance. RT-PCR also confirmed the expression of TLRs in the relevant cell lines, 
and that control cells did not express TLRs. On this basis, we can assume that changes in KSHV 
infection levels in the TLR-expressing cell lines seen by flow cytometry compared to control cell 
lines are due to receptor expression. 
sqPCR identified novel TLRs whose expression appears to be affected by KSHV infection. This 
can now be further investigated using quantitative PCR methods, which would provide a more 
sensitive identification method over ethidium bromide, and allow precise quantification and 
comparison of differences in template levels between infected, uninfected and control samples.  
4.1 Future Directions  
We have investigated the effect of ectopic TLR expression on KSHV infection and formed a 
basis for which more detailed analyses in KSHV-tropic cells, such as HUVECs, can be done. 
Given that B cells express a majority of TLRs (Bourke et al. 2003) and KSHV latency occurs in B 
cells (Dupin et al. 1999), the experiments should be confirmed in these cells to closer resemble in 
vivo infection. The expression of these TLRs in vivo may change the effect that they have in 
KSHV infection. TLRs are expressed on a range of cell types, and often more than one on a 
single cell type (Table 1). A further direction could be taken in investigating the mechanism 
behind the sensitivity of KSHV infection to the ectopic expression of TLR 2, 3, 4 and 5 
expressing cell lines.  Given that expression of TLRs has been seen on KSHV tropic cells, as well 
as immune surveillance cells, such experiments would be analogous to clinical situations. 
Receptors of innate immunity act in concert to enhance a response to viral infection (Sorensen et 
al. 2008). Therefore, it would be of interest to investigate the effect of the expression of TLRs in 
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combination on KSHV infection. For example, investigating combinations of TLRs that act as 
heterodimers with other TLRs and endogenous cellular receptors, such as TLR 2/RP105, TLR 
2/CD36, TLR4/RP105 and TLR 4/CD14 heterodimers. Different combinations of receptors 
can affect ligand interactions (Kang et al. 2009), which may be relevant for viral recognition, 
manipulation and downregulation. Similarly, concerted expression of TLRs may have a greater, 
lesser or no effect on KSHV infection efficiency. TLR 2 and 9 are required together for detection 
of HSV-2 in mouse models (Sorensen et al. 2008). Based on our data, it would be of interest to 
investigate the effect of TLR 7 in concert with TLR3, which is similarly situated in the cell and 
detects ssRNA (Table 1). Nucleic acid detecting TLRs may overlap in ligand binding specificity, 
and thus the expression of more than one may counteract KHSV evasion techniques, such as 
mRNA degradation or transcriptional downregulation. 
Degradation of mRNA is a recognized method of viral evasion from immune detection. HSV-1 
induces ICP0 expression, a cellular protein which destabilises mRNA (Kummer et al. 2008). 
KSHV encodes a host-shutoff and exonuclease protein (Sokoloski et al. 2009), and HSV encodes 
a similar protein, both of which have exonuclease activity (Glausinger and Ganem, 2004, Korom 
et al. 2008). EBV BGLF-5 protein is known to promote mRNA degradation (Rowe et al. 2007), 
and is a homolog of KSHV host-shutoff and exonuclease protein. Given the similarities between 
the two proteins, it is possible that the TLR 7 mRNA decrease seen in our experiments is 
orchestrated by KSHV host-shutoff and exonuclease protein, and this is an interesting avenue for 
the exploration of KSHV interactions with TLR-induced pathways. However, mRNA levels can 
also be affected at a transcriptional level, as previously mentioned, and it would be of interest to 
investigate this also. For example, gene transcription may be inhibited by the viral RTA 
transactivator (Bechtel et al. 2005). 
We have analysed the effect of ectopic TLR expression on KSHV infection, and the effect of 
KSHV infection upon TLR expression levels to find that TLRs that are affected by KSHV 
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infection do not necessarily effect KSHV infection. Notably, TLR 7 expression does not affect 
KSHV infection efficiency, but KSHV infection downregulates TLR 7 mRNA levels. This 
information provides a solid foundation for future work into the interactions of a prominent 
herpesvirus with human innate immune receptors, and may provide relevant information for 
therapeutic targetting. 
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 Abstract 
Human papillomavirus (HPV) is responsible for 5.2% of the world’s cancer burden, and 
is associated with cervical, ano-genital, and head and neck cancers. Interaction of high-
risk E6 proteins with cellular PDZ-domain containing proteins such DLG1 INADL, 
SCRIB and PTPN13, has been shown to contribute to invasive and metastatic properties 
of advanced carcinomas. Investigation into PDZ proteins not only presents an insight 
into the mechanism and consequences of host PDZ protein gene expression changes 
that contribute to the progression of cancer, but also highlights important cellular 
oncoproteins and tumour suppressors. Here, we investigate the impact of HPV16 and 
HPV18 infection, in a keratinocyte model of HPV replication, on the expression of 
DLG1, INADL, PTPN13 and SCRIB. Gene expression array and qPCR analysis showed 
increased expression of DLG1, INADL and PTPN13, but not SCRIB, in the HPV 
genome containing cells. However, the upregulation of gene expression was lost upon 
extended passage of these cells. Such HPV-induced changes in expression of DLG1, 
INADL and PTPN13 are suggested to be a cellular response to HPV replication, one 
that might be negated by the subsequent ubiquitin-mediated degradation of the protein, 
directed by E6. 
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Human Papillomavirus and PDZ-domain containing proteins 
1. Introduction 
1.1 Cancer and Epithelia 
Cancer is a disease of cells, resulting from the accumulation of mutations leading to 
deregulation of cell proliferation and cell migration (Hanahan and Weinberg, 2000). 
Around 90% of human cancers are derived from epithelial cells (Tanos and Rodriguez-
Boulan, 2008); the cells which form the monolayers or multi-layered tissues at interfaces 
between the organism and the outside world. Epithelial tissues are involved in complex 
functions necessary for an organism’s homeostatic control, such as cellular trafficking, 
migration and interactions, for which epithelial polarity is essential (see Etienne-
Manneville, 2008). The polarity of tissue, and thus the polarity of the individual cells, is 
determined and regulated by a number of interacting protein complexes forming 
scaffolds and trafficking systems (Figure 1). As such, alteration and deregulation of 
epithelial polarity molecules leads to abnormal cellular trafficking, signalling and 
migration, and contributes to the development of carcinomas and progression to an 
invasive phenotype, which are hallmarks of epithelial-derived cancers (Figure 2) (Tanos 
and Rodriguez-Boulan, 2008). Epithelial cancers are also characterized by epithelial-
mesenchymal transition (EMT) (Huber et al. 2005) where cell phenotype is altered; cell to 
cell junctions become disrupted so that neighbouring cells begin to dissociate from each 
other, no longer making tight junctions (TJs) and forming the interface that characterises 
their function. With such an important role, control of cell polarity is a major issue in the 
treatment of cancer patients, and the targeting of such pathways therapeutically 
represents a wide area of potential research.  
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Maintenance of epithelial polarity and cell-cell junctions involves a large and diverse 
number of proteins, many of which contain multiple PDZ-domains. The PDZ 
(PSD/Dlg/ZO1) domain is an evolutionarily conserved domain of approximately 90 
amino acids. It forms a hydrophobic pocket that interacts with specific sequences within 
or at the C terminus of target proteins (Songyang et al. 1997). The presence of multi-
PDZ domains within a protein allows it to serve a structural role and act as a scaffold for 
the organisation of large protein complexes at a specific sub-cellular location. PDZ-
domain containing proteins are generally involved in cell polarity, although they have 
associated roles in signalling and may yet have roles that are not elucidated (Giallourakis 
et al. 2006). Thus there is significant oncogenic potential if these proteins are deregulated 
at a transcriptional, translational or post-translational level. 
1.2 Human papillomavirus and oncogenesis 
Human papillomavirus (HPV) is necessary for the transformation of mucosal epithelium 
in the development of cervical and ano-gential cancer (Walboomers et al. 1999). There 
are 106 types of HPV which infect humans, divided into the non-oncogenic, ‘low-risk’ 
types, and the oncogenic, ‘high-risk’ types (Table 1). Oncogenesis is a rare side effect of 
infection by high-risk types of HPV; persistent HPV infection leads to increased 
proliferation of epithelia and decreased response to apoptotic signals, leading to the 
accumulation of mutations that favour cancerous growth. High-risk types include 
HPV16 and HPV18, which are responsible for 5.2% of the world’s cancer burden 
(Parkin, 2006), and express the principal HPV oncoproteins E6 and E7. These 
oncoproteins act in synchrony to utilise host transcriptional and cellular proteins to 
induce the host-cell proliferation. The consequence E6 and E7 expression is genomic 
instability, disrupted apoptotic regulation and immortalisation required in transformation 
(see McLaughlin-Drubin and Munger 2009). The expression of E6 and E7 oncoproteins 
is retained in cancers (Doorbar, 2005).  
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HPV is a small, double-stranded DNA-containing virus that infects basal epithelia, and 
replicates in synchrony with the cells (Figure 3). As cells migrate upwards they would 
normally differentiate and thus exit the cell cycle, but HPV pushes the cell back into the 
cycle, mainly via inactivation of viral E7 protein with cellular pRb (Dyson et al. 1989, Du 
and Pogoriler, 2006). The viral genome is multiplied, so that there are hundreds of copies 
per cell, by hijacking cell machinery and creating an environment conducive to virion 
production (Doorbar, 2005). This over-proliferation activates the cellular p53 protein, 
whose actions are countered by viral E6 protein (Scheffner et al. 1990, McLaughlin-
Drubin and Munger 2009). 
1.3 PDZ Proteins 
PDZ domain-containing polarity proteins are common cellular targets for inactivation by 
oncoproteins encoded by the tumour viruses HPV, human T-lymphotrophic virus 
(HTLV-1) and adenovirus type 9, which are influential in cervical cancer, adult T-cell 
leukaemia and mammary cancers in experimental animals, respectively. These oncogenic 
viruses promote tumour growth via interactions with cellular polarity proteins, resulting 
in deregulation of cell polarity and integrity; interactions with PDZ proteins contribute to 
virus-mediated tumourigenesis. (see Javier, 2008). 
It is the E6 protein of high-risk HPV types that is known to interact with cellular PDZ-
domain containing proteins. The E6 protein of high-risk, but not low-risk, HPV types 
contains a class I PDZ-binding motif (PBM) at its C-terminus (Figure 4). The PBM is 
required for E6-mediated transformation of cultured rodent cells (Kiyono et al. 1997) and 
immortalised keratinocytes (Watson et al. 2002). The absence of PBM in low-risk HPV 
implies that interactions between E6 and cellular PDZ-domains are significant in viral 
transformation of epithelia; expression of high-risk E6 protein correlates with metastatic 
skin cancer formation in transgenic animals (Song et al. 1999), and is known to cause 
EMT of human keratinocytes (Watson et al. 2003). The ability of E6 and E7 together to 
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increase tumour size in the cervix is dependant upon the binding ability of E6 to its 
PDZ-domain containing proteins (Nguyen et al. 2003). Thus, E6-mediated disruption of 
PDZ proteins, which regulate host-cell polarity and adhesion, may contribute to 
metastatic properties of HPV-driven tumours. 
Viral disruption of cell polarity aims to benefit viral life cycle by aiding proliferation of 
basal cells, and interaction of E6 PBM with a subset of cellular PDZ proteins appears to 
be important for HPV life cycle and genome maintenance (see Pim and Banks, 2010), 
with cancerous effect in the host cells. High-risk HPV E6 binds to a specific domain 
within a target protein depending upon the viral PBM sequence, a non-canonical 
upstream amino acid sequence, and on the sequence of the PDZ domain sequence of the 
target protein (Thomas et al. 2008). Despite the presence of many PDZ domains in the 
PDZ-containing targets of HPV E6, only one PDZ domain is thought to be targeted 
(Thomas et al. 2001, 2002). The interactions appear to be highly specific. As well as this 
specificity, E6 proteins from different high-risk types of HPV appear to have different 
affinities and specificities for PDZ-domain containing target proteins, depending on the 
E6 and on the localisation and modification of the PDZ protein (Thomas et al. 2001, 
Massimi et al. 2006). For example HPV18 has a higher affinity for DLG1 and the MAGI-
1 proteins than HPV16, which has higher affinity for SCRIB protein (Pim et al. 2009, 
Thomas et al. 2005, Kranjec and Banks, 2010). This difference in affinity can be switched 
by altering the PBM motif in the HPV16 and HPV18 E6 proteins (Thomas et al. 2001). It 
is yet to be seen whether the affinity for different PDZ proteins correlates with ability to 
cause invasive cancers.  
E6 forms the E6-associated ubiquitin ligase complex. Via this ligase activity and PBM, it 
is thought that high-risk HPV E6 protein couples PDZ-domain containing proteins to 
ubiquitin, and targets the proteins for proteosomal degradation. HPV18 E6 appears to 
induce the degradation of certain pools of DLG1 in cell culture, potentially due to the 
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different localization and/or phosphorylation state of the protein (Massimi et al. 2004, 
2006). 
To date, fourteen PDZ domain-containing proteins that interact with high-risk HPV E6 
is have been identified (Table 2). These proteins have varying roles in cell polarity, tissue 
integrity, scaffold formation, signalling and intracellular trafficking (Table 2). Although 
most of E6 PDZ-domain targets appear to be degraded via their interaction with E6, it is 
not clear what the consequences of interaction are for PTPN13 and TAX1BP3, and 
INADL is degraded in the absence of E6 PBM (Storrs and Silverstein, 2007). 
DLG1, INADL, PTPN13 and SCRIB are all human PDZ-domain containing proteins 
that are involved in the maintenance of cell junctions and cell polarity and have been 
implicated in cancer progression separately from HPV influence. 
1.3.1 DLG1 
DLG1 was identified as a tumour suppressor protein in Drosophilia, where null mutations 
lead to loss of apical-basal polarity and to neoplastic growth (Woods et al. 1996, Woods 
and Bryant, 1991). The protein belongs to the membrane-associated guanylate kinase 
(MAGUK) family (Lue et al. 1994, Müller et al. 1995), which localise to cell–cell contact 
sites and are required for junction formation and the establishment of cell polarity 
(Humbert et al. 2003, Laprise et al. 2004). Consistent with this, DLG1 is made up of 
several interaction modules, including an SH3 domain (Figure 5), which are involved in 
protein-protein interactions (Gonzalez-Mariscal et al. 2000), allowing DLG1 to act as a 
molecular scaffold complex, organising target proteins into signalling complexes and 
localising them correctly (Kim and Sheng, 2004). As is part of the scribble complex with 
Lgl and SCRIB proteins, DLG1 is involved in tight junction formation and mitotic 
spindle formation, as well as cell polarity and attachment (Albertson and Doe, 2003). 
However, as DLG1 is expressed in epithelial tissue across the body as well as neurons, 
the protein is likely to have context-dependent functions (Cavatorta et al. 2008, Frese et 
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al. 2006). DLG1 was the first identified cellular PDZ protein target of high-risk E6 PBM 
(Kiyono et al. 1997, Lee et al. 1997). High-risk E6 interacts with the PDZ1 and 2 domains 
of DLG1 and recruits ubiquitin ligase, leading to the proteosomal degradation of DLG1 
(Gardiol et al. 1999). However, there is a nuclear subset of phosphorylated DLG1 protein 
(Massimi et al. 2004 and 2006), and thus HPV E6-mediated degradation does not 
completely eliminate DLG1 in epithelia.  
1.3.2 SCRIB 
As well as acting in the scribble complex, SCRIB protein prevents apoptosis and has 
been designated a tumour suppressor (Liu et al. 2007). The protein has been shown to 
regulate cell migration in a context dependant fashion (Humbert et al. 2006). Loss of 
SCRIB function presents a similar phenotype to DLG1 mutations, reduced levels of both 
DLG1 and SCRIB in carcinomas is associated with increased dysplasia and invasive 
phenotype (Gardiol et al. 2006, Martin et al. 2004). Both proteins are lost at the later 
stages of many other epithelial cancers (Fuja et al. 2004; Navarro et al. 2005), indicating 
that the complex they form, as well as the other roles they perform within a cell, is a 
significant obstacle to metastatic cancer formation. HPV16 E6 levels are increased by 
SCRIB in a PDZ-dependent fashion (Nicolaides et al. 2011), suggesting that although the 
PDZ protein may play a role detrimental to viral promotion of proliferation, the protein 
may affect viral stability, and that E6 selectivity in targeting the PDZ protein is important 
to viral life persistence.  
1.3.3 INADL 
Like DLG1 and SCRIB, INADL, is associated with cellular tight junctions (TJ). The 
protein regulates the formation and localization of TJs, as well as regulating the 
directional migration of epithelial cells and organising signalling and effector molecules 
on a scaffold (Shin et al. 2007, Chen et al. 2009). Interactions of INADL protein with 
adenovirus 9 E4 ORF oncoprotein causes mislocalisation of the cellular TJ complexes 
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and correlates with viral oncogenic ability (Latorre et al. 2005). As viruses have evolved 
strategies targeting similar polarity proteins in oncogenesis, INADL is likely to be a 
relevant protein affected during HPV-driven oncogenesis. 
1.3.4 PTPN13 
PTPN13 is a fas-associated, non-receptor phosphatase that contains five PDZ domains, 
as well as a phosphatase domain and a cell membrane localisation domain (Figure 5). 
PTPN13 protein is increased in aggressive breast cancers (Glondu-Lassis et al. 2010), and 
certain genetic polymorphisms are known to increase the risk of squamous cell 
carcinomas in the head and neck (Niu et al. 2009), a cancer that HPV is increasingly 
becoming associated with (Shillitoe, 2009). PTPN13 dephosphorylates fas protein and 
interacts with src kinase, suggesting a role for PTPN13 in fas-mediated apoptotic 
signalling. Unlike the other proteins described here, this is the only one not yet associated 
with a cell-to-cell junctions. However, it has been linked to cancer progression in the 
absence of viral agents, and interacts with high-risk HPV E6 proteins, and is therefore of 
interest to HPV-associated carcinomas. 
1.4 Hypothesis, Aims and Objectives 
The HPV infectious cycle is closely aligned with the differentiation programme of 
keratinocytes. Investigation into the virus-host interactions involved in this alignment are 
supported by a cell-based model of HPV replication. This model is based upon primary 
keratinocytes stably transfected with episomal forms of high-risk HPV DNA. The viral 
DNA is stably replicated as extrachromosomal plasmids within the keratinocytes and 
these cells are representative of infected basal epithelial cells (Frattini et al. 1997). 
Affymetrix gene expression arrays, performed on primary foreskin keratinocytes stably 
transfected with HPV16 and HPV18 genomes, showed upregulation of mRNAs coding 
for a subset of the E6 PDZ-domain containing proteins. The most significantly 
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upregulated PDZ-domain containing proteins were DLG1, INADL and PTPN13, whilst 
SCRIB showed only moderate upregulation of expression (Table 3).  
On the basis of this data, we hypothesize that replication of the oncogenic viral DNA in 
keratinocytes induces a host defence mechanism that includes the transcriptional 
upregulation of selective PDZ-domain containing proteins. Downstream inactivation of 
these targets by E6 mediated proteosomal degradation may be a key mechanism of the 
virus to allow virus replication.  
The first aim of the study is to verify the results of the microarray analysis by quantitative 
PCR (qPCR) and the second to determine if this is an early or late response to viral 
replication in primary keratinocytes. The third aim of this study is to investigate the 
effect of HPV-PDZ interactions on cell morphology, by examining whether knockdown 
of DLG1 using shRNA technology will rescue any invasive phenotype. 
 9 
 
2. Methods 
Unless otherwise stated, materials and chemicals were obtained from commercial sources. 
2.1 Cells and Cell Culture 
Primary human foreskin keratinocytes (HFKs) isolated from neonate foreskins were cultured 
from frozen stocks on irradiated 3T3 J2 fibroblast feeder cells in complete E Media (CEM). 
CEM consists of Dulbecco’s modified eagle media (DMEM, 60% v/v, Gibco), Ham’s F12 (32% 
v/v, Gibco), PenStrep (2% v/v, Gibco), hydrocortisone (0.1% v/v, Sigma), foetal bovine serum 
(FBS, 10% v/v, Gibco), mouse epidermal growth factor (EGF, 0.5 % v/v, BD), L-glutamine (2% 
v/v, Gibco), cholera toxin A (0.1% v/v, ICN Biomedical), insulin (0.2% v/v, Sigma), transferrin 
(0.2% v/v, Sigma), tri-iodo–lL-thyronine T3 (4 nM, Sigma) and adenine (36 μM, Sigma). 
Cell lines containing the HPV16K (Kanda et al. 1987, Roden et al. 1996) or HPV18 (Wilson et al. 
2007) episomal genome were cultured alongside untransfected cells derived from the same 
donor. The HPV16 and HPV18 replicating cell lines from this particular donor were generated in 
Dr Roberts’ laboratory by Drs Constandinou-Williams and Roberts. The untransfected cells serve 
as a control and were treated in parallel to the transfected cells. At each passage, aliquots of 5x105 
cells were pelleted by centrifugation, washed with phosphate buffered saline (PBS) and stored at -
80oC for RNA extraction 
3T3 J2 cells were cultured in DMEM supplemented with L-glutamine (2% v/v, Gibco) and foetal 
bovine serum (FBS, 10% v/v, Gibco). This will be referred to as J2 medium. Cells were cultured 
and harvested for irradiation as required. 3T3-J2 cells were irradiated with 40 grays and plated at a 
density of 2x106 cells per 10 cm3 dish overnight for preparation as feeder cells. HFK cells were 
seeded onto 3T3-J2 cells at a density of 2x105 cells. 
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Lung carcinoma-derived H1299 cells were cultured in DMEM supplemented with foetal calf 
serum (FCS, 10% v/v) and L-glutamine, (2% v/v, Gibco) which will be referred to as H1299 
medium.  
HFK models of HPV life cycle are initially established by cotransfection of early passage (p3) 
primary human foreskin keratinocytes with recircularised HPV16 or HPV18 genomes and a 
plasmid encoding the gene for neomycin resistance (Wilson et al. 2007). After transfection the 
cells are seeded onto feeder layers of irradiated J2 3T3 fibroblasts and cells expressing the 
resistance marker are selected using the antibiotic G418 for 8 days during which time the cell are 
often passaged again at least once or twice (e.g. p3/p2, p3/p3); after this time the antibiotic is 
removed from the media. Clones that emerge from these antibiotic free cultures are eventually 
pooled once they reach the size of a 10 pence coin, and then expanded by further growth on J2 
3T3 feeder layers. At this point, the actions of HPV E6 and E7 early proteins are the driving 
force for the extended growth of these cells. Microarray analysis was performed on RNA 
extracted from the cell lines at this stage of expansion (p3/p4). Establishment and maintenance 
of HPV episomes was confirmed by Southern blot analysis of total DNA (Wilson et al. 2007).  
2.2 Transfection of shRNA and protein analysis 
H1299 cells were harvested and seeded at a density of 2x105 cells in a 6 well plate, for incubation 
overnight in the appropriate media before transfection of cells at 90% confluency. For 
transfection, cells were treated with Lipofectamine 2000 (Invitrogen) and 5 μg of DNA, premixed 
at room temperature for 20 min. Parallel to this, cells were transfected with green fluorescent 
protein (GFP) as a control. Cells, DNA and Lipofectamine were incubated for three hours and 
quenched with warmed H1299 medium (37oC). Initial observations under a fluorescence 
microscope before cells were harvested (at 12, 24, 48 and 72hr) showed successful transfection, 
seen as green fluorescence emission. At the appropriate timepoint (12, 24, 48 or 72 hours), cells 
were harvested for protein quantification and analysis by western blot. To harvest, cells were 
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washed with ice-cold saline and lysed using urea-tris-βmercaptoethanol (UTB) lysis buffer (9 M 
urea, 250 mM tris, 50 mM NaCl, 150 mM βmercaptoethanol) before sonication for 30 secs. 
Lysed cells were centrifuged (450 x g, 20 min) and the supernatant transferred for protein 
quantification. Protein concentration was quantified by Bradford assay (BioRad) and 20 or 30 μg 
of protein was resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Once SDS-
PAGE was complete, protein was transferred to PVDF membrane (15 V, overnight). The 
presence of protein on the membrane was confirmed by Ponceau-S staining. Membranes were 
incubated in 2% milk in phosphate-buffered saline (PBS), before separate halves were probed 
with an anti-rabbit DLG1 polyclonal (NAG) antibody (Roberts et al. 2007) or mouse monoclonal 
antibody specific to GAPDH, for at least 2 hours. Membranes were then washed in PBS and 
probed with appropriate secondary antibodies conjugated to horseradish peroxidase (HRP). All 
antibodies were diluted in 2% milk-PBS. The HRP reaction was carried out using enhanced 
chemiluminescence (ECL) reagents (GE Healthcare) and visualized by exposure to X-ray film. 
Resulting images were scanned in and subject to densitometry using the ImageJ program 
(http://rsbweb.nih.gov/ij/), standardising each lane to the intensity of GAPDH to account for 
loading, and then all samples to GFP transfections to assess the extent of DLG1 knockdown. 
Combinations of four shRNA plasmids were tested to identify the optimum combination for 
DLG1 knockdown (Table 4). Having identified the 5 most efficient knockdown combinations, 
using the standard incubation time of 24 hours, the combinations were subject to a time 
titrations, where transfected cells were lysed at 12, 24, 36 or 48 hours. These samples were then 
treated as above; subject to SDS-PAGE and western blotting. In all experiments, GFP 
transfected cells served as a control for successful transfection and for showing a normal level of 
DLG1 protein. 
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2.3 RNA isolation and cDNA synthesis 
Approximately 5x106 cells were isolated from each HFK culture; one transfected with HPV16, 
one with HPV18 and one untransfected. Messenger RNA (mRNA) was extracted using the 
Qiaquick RNA extraction kit (Qiagen), according to the manufacturer’s instructions. A DNase 
treatment step was included. The RNA concentration of each sample was measured (ratio 
A260/280), on a NanoDrop ND-1000 Spectrophotometer (Labtech International). The same 
mRNA used for the gene expression arrays was used to examine the effect of HPV early after 
transfection. This mRNA was extracted from early passage HFKs (p3) for untransfected control, 
and from the established HPV16 and HPV18 transfected cells once they had been expanded in 
culture (p3/p4). Alongside this, later passage samples, taken at p3/p8 from the same donor cells 
grown at a different time, were analysed. 
Complementary DNA (cDNA) synthesis was performed using 250 ng of DNase-treated RNA, 
random hexodeoxynucleotide primers and the Moloney murine leukemia virus (MLV) reverse 
transcriptase (MLV RT, Promega) in the presence of RNase inhibitor and nucleotides (10 mM) 
(Promega). The RNA, nucleotides and primers were heated to 65oC for 5 min and chilled on ice, 
in order to denature any proteins present in the mixture before addition of the polymerase and 
RNase inhibitor. The reaction (25 μl) was incubated at 37oC for 50 min followed by inactivation 
of the MLV RT by heating to 70oC for 15 min. Resulting cDNA was purified using a Qiaquick kit 
(Qiagen) according to the manufacturer’s instructions and quantified using a NanoDrop ND-
1000 Spectrophotometer (ratio A260/280).  
2.4 Primer design, optimization and qPCR 
Polymerase chain reaction (PCR) primers were designed using primer 3 software 
(www.primer3.com). Human genomic sequences were obtained from the UCSC genome browser 
(www.ucsc.com). Basic local alignment search tool (BLAST) searches 
(http://www.ncbi.nlm.nih.gov/BLAST/) were performed in all cases to ensure that primers were 
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not complementary to other regions of the genome and bound specifically to the target 
sequences. The specific primer sequences are listed in Table 5. Initially a temperature gradient 
was set up to find the optimum temperature for each primer pair. Each 25 μl cDNA synthesis 
reaction contained; 5 μl cDNA, 12.5 μl hotstart Taq mastermix (Thermo Scientific) and 10 pmol 
of forward and reverse primers. DNA fragments of expected length were visualized by 2% 
agarose gel electrophoresis and ethidium bromide staining.  
qPCR reactions were set up on ice and performed in 96-well reaction plates (Applied 
Biosystems). Each 25 µl reaction consisted of 40 ng of cDNA, 12.5 µl of Sybr green mastermix 
(Applied Biosystems) and 10 pmol of forward and reverse primers. All samples were run in 
triplicate in the ABI Prism 7700 Sequence Detection System (Applied Biosystems). Samples were 
subjected to a denaturation step at 95°C for 10 min followed by 40 cycles of denaturation at 95°C 
for 15 sec, annealing at 60°C for 30 sec and an extension step at 72°C for 1 min.  
Primers specific to a housekeeping gene were also run on each qPCR plate, to account for 
loading variability. In order to ensure no variability in housekeeping gene levels, three were 
examined, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), β2-microglobulin (B2M) and 
hypoxanthine-guanine phosphoribosyltransferase-2 (HPRT2). Dissociation curves were 
performed to ensure specific amplification of the correct template. 
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3. Results 
This study has used a primary HFK based model of the HPV life cycle to examine the effect of 
HPV16 and HPV18 genome expression on the cellular mRNA level of E6 targeted PDZ-domain 
containing proteins. This cell-based model represents a powerful system in which to study the 
function of E6-PDZ domain protein interactions. With this in mind, the study investigates the 
mechanisms of silencing specific PDZ domain proteins. 
3.1 Genome wide expression analysis. 
 Affymetrix gene expression arrays performed in the school of Cancer Sciences by Professor 
Ciaran Woodman, Dr Sally Roberts and Dr Sarah Leonard and colleagues were used to identify 
PDZ-domain containing proteins which are deregulated following transfection of primary HFKs 
with episomal forms of HPV16 and HPV18 genomes. These arrays identified the three PDZ-
domain containing proteins DLG1, INADL and PTPN13 that were significantly upregulated at 
the mRNA level in both HPV16 and HPV18 transfected HFKs when compared to untransfected 
HFKs, (Table 3). Another PDZ-domain containing protein, GOPC was upregulated on the 
microarray, but was considered absent on the array and therefore not included in the validation. 
Other PDZ-domain containing proteins had either little or no significant changes in expression 
(Table 3). DLG1, INADL and PTPN13 were therefore chosen for further validation using 
qPCR. As a control, SCRIB was included in the qPCR analysis, because array data showed it was 
not significantly deregulated following transfection with either HPV16 (1.57 fold) or HPV18 
(2.01 fold). 
3.2 Optimisation of DLG1, INADL, PTPN13 and SCRIB primers  
Primers designed to specifically amplify SCRIB, DLG1, INADL and PTPN13 were optimised on 
cDNA from untransfected HFKs, in order to find the most efficient annealing temperature for 
each primer pair. SCRIB, DLG1, INADL and PTPN13 primers annealed at a range of 
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temperatures, however each target sequence amplified at 60oC (Figure 6). Therefore, all primers 
could be utilised for qPCR in subsequent experiments, applying an annealing temperature of 
60oC to all samples. 
3.3 Housekeeping gene analysis 
Initially, GAPDH served as a housekeeping gene in qPCR reactions to account for experimental 
variability. However, its expression was consistently variable between cDNA samples (Figure 7, 
panel A); there are about three cycles between transfected samples and the untransfected control. 
The significance of the variability was not statistically tested. However, it was obvious by 
comparison that B2M and HPRT2 were less variable than GAPDH between cDNA samples; 
they differ only by half a cycle at most (Figure 7, panels B and C). The difference in expression 
between each of the samples for B2M and HPRT2 is slight, but because the HPRT2 expression 
is the least variable, it is this control that is used in further qPCR analyses. 
3.4 Establishment of HPV16 and HPV18 genomes in primary cells is associated with an upregulation of 
DLG1, INADL and PTPN13 gene expression 
qPCR analysis was used to validate the changes in gene expression of the PDZ-domain 
containing proteins observed in the microarray study; the same donor primary keratinocytes were 
used in the qPCR analysis. qPCR analysis showed upregulation of DLG1, INADL and PTPN13 
in low passage HFKs replicating episomal HPV16 or HPV18 genomes (Figure 8, panel A). As a 
general trend, transfection with HPV16 caused a higher-fold upregulation of DLG1, INADL and 
PTPN13 than transfection with HPV18, although PTPN13 shows the least difference between 
HPV16 and HPV18-induced increases in gene expression (Figure 8 panel A). DLG1 showed the 
highest relative upregulation; expression increased 23 and 7-fold following transfection of 
HPV16 and HPV18, respectively (Figure 8, panel A). Expression of INADL increases 14-fold 
upon HPV16 genome transfection, and 5-fold upon HPV18 genome transfection (Figure 8, 
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panel A). However, expression of SCRIB gene shows little, if any, change in level upon 
transfection of either HPV16 or HPV18 as expected (Figure 8, panel A). 
In contrast to samples extracted from the HPV DNA containing cell lines at early passage, 
cDNA from the higher passage cell lines showed little change in DLG1, INADL, PTPN13 or 
SCRIB expression in HPV16 and HPV18 genome transfected cells, compared to the 
untransfected control (Figure 8 panel B). Unlike the low passage samples, there is no general 
trend between cells containing HPV16 or HPV18. DLG1 and PTPN13 expression shows no 
change upon HPV genome expression and, if anything, HPV appears to downregulate SCRIB 
and INADL to a small extent (Figure 8 panel B), however the statistical significance of the 
changes in gene expression was not tested. 
3.5 Silencing RNA optimisation 
Transfection of combinations of four plasmids encoding shRNA to DLG1 into H1299 cells 
showed that, after 24 h transient expression, a combination of all four and a combination of 
plasmids 1 and 3 knocked down DLG1 expression most effectively, lowering levels of the 
protein to approximately 30% of the control, GFP-transfected cells (Figure 9). Plasmid 4 also 
achieved a significant decrease in DLG1 levels, lowering protein levels to 45% of control (Figure 
9). Knockdown is visible by eye and confirmed by densitometry of western blot analysis (Figure 
9).  
On testing to find the optimum length of shRNA incubation time that lead to the lowest level of 
DLG1 protein, it was found that generally 12 hours of transient expression of the shRNA 
provided the best decrease of DLG1 levels in all combinations tested (Figure 10). By 72 hours, it 
appears that the transient effects of shRNA have markedly reduced, and levels of DLG1 return 
to around the level of control in most cases (Figure 10). Use of plasmids 1 and 4 individually led 
to a large decrease in DLG1 protein, compared to normal levels, most notably following a 12 
hour incubation where protein levels are taken down to approximately 55% and 16% of control 
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DLG1 levels, respectively (Figure 10). Of the combinations, transfecting all four shRNAs seems 
to be the most efficient for DLG1 knockdown. A combination of all four plasmids led to lower 
DLG1 levels at all timepoints, and thus seems to be the most consistent (Figure 10). A 12 hour 
incubation is the most efficient length of time, leading to a reduction of DLG1 protein levels to 
35% of control (Figure 10). Unlike the previous transfection, a combination of plasmids 1 and 3 
does not appear to be very effective in this time optimisation (Figure 9 and 10).  
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4. Discussion 
HPV16 and HPV18 episomal genome expression in early passage neonate HFKs upregulates 
transcription of PDZ-domain containing proteins DLG1, INADL, PTPN13, but has no affect 
on the transcription of SCRIB. The qPCR results verify results from the gene expression 
microarray analysis, showing a larger increase in expression of DLG1, INADL and PTPN13 
when cells were transfected with HPV16, compared to HPV18. These findings are novel and 
have shown for the first time an effect of HPV replication on the gene expression of a subset of 
PDZ-domain containing proteins.  
The increase in DLG1, INADL and PTPN13 gene expression may be a cellular response to HPV 
infection; one that requires the virus to negate the consequence of the upregulation of these 
genes through the action of E6 targeting DLG1, INADL and PTPN13 proteins for proteosomal 
degradation. Such a response is similar to the activation of p53 upon viral replication mediated by 
the actions of E7 on the pRb pathways, which are subsequently countered by E6-induced 
degradation of the p53 protein. Perhaps, however, DLG1, INADL and PTPN13 proteins are 
necessary for the establishment of HPV genomes in primary keratinocytes, and so the increase in 
expression of these genes is a viral response to counteract detrimental affects of E6. If increased 
levels of DLG1, INADL and PTPN13 proteins are required for viral life cycle, then degradation 
of PDZ-domain containing proteins by E6 may be inhibited in cells; it has already been shown 
that E6 mediated degradation of PDZ substrates is negatively regulated by protein kinase A 
phosphorylation of the E6 PBM (Kuhne et al. 2000). This is an example of a posttranslational 
modification that would allow differential degradation of the PDZ substrates during the HPV life 
cycle; degradation of DLG1, INADL and PTPN13 may not be favourable at the early stages of 
the virus life cycle, and hence expression of these genes is increased. 
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Although several cellular PDZ-proteins have been identified as interacting with high-risk E6 
proteins (Table 2), it is yet to be seen whether these proteins are genuine targets of E6-mediated 
proteosomal degradation. Indeed, both DLG1 and SCRIB are lost in the later stages of non-HPV 
related carcinomas (Fuja et al. 2004; Navarro et al. 2005), and the loss of these proteins may be a 
consequence of cancer development in these tissues, rather than as a result of HPV infection. 
However, phenotypic similarities between HPV-associated cancers and loss of polarity proteins 
strongly suggest a link between HPV interaction with PDZ-proteins and subsequent oncogenesis. 
For example, silencing RNA (siRNA) depletion of PTPN13 in tonsillar epithelia presents the 
same loss of polarity phenotype as expression of E6 within these cells, whilst overexpression of 
PTPN13 reverses the effects (Javier and Rice, 2011). The phenotypic similarity between HPV 
infected and PTPN13 depleted cells indicates an important role for PTPN13 protein in epithelial 
polarity, a characteristic abnormality in HPV-induced epithelial tumours. The HPV16 and 
HPV18 PBMs are the C-terminal motifs of ETQL and ETQV respectively, which are required 
for the virus’ promotion of EMT, immortalisation of human tonsil keratinocytes, induction of 
anchorage-independent growth and inhibition apoptosis in epithelia (Watson et al. 2003, James et 
al. 2006, Spanos et al. 2008), all of which are phenotypic consequences attributable to the 
depletion of PDZ proteins. Because the E6 PBM is the only protein-protein interaction unique to 
high-risk HPV types, and the protein is known to target proteins for ubiquitin-mediated 
degradation (Thomas et al. 2008), it is likely that decrease of cellular PDZ proteins is due to HPV 
E6 PBM-mediated proteosomal degradation. Furthermore the E6 PBM is crucial to tumour size 
and frequency, mediated by E7 and E6 cooperation in the cervix (Shai et al. 2007), which implies 
a cooperative role for the E7 oncoprotein in PDZ deregulation. High-risk HPV E6 
downregulation of PDZ proteins may allow growth of cells regardless of anti-growth signals that 
are likely to be triggered from neighbouring cells in response to over-proliferation, allowing the 
virus to proliferate with the cell. But, if this deregulation is detrimental to the life of the cell it is 
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also detrimental to the life of the virus. For this reason, HPV may utilise mechanisms to limit 
such damage to the host, including the upregulation of DLG1, INADL and PTPN13 gene 
expression, in order to prevent cellular protein levels from dropping below a critical level. 
Evidence suggests that E6 targets specific pools of PDZ proteins (Massimi et al. 2004). It is 
possible that E6-resistant PDZ protein pools are required to function for the benefit the HPV 
life cycle, and that increased gene expression enables the protein level of these pools to be 
increased, or at least maintain the required level for the viral persistence. This may be a reason 
behind the high level of increased DLG1 gene expression, compared to the increase in levels of 
INADL and PTPN13 gene expression. DLG1 is known to exist in nuclear and cytoplasmic-
localised pools, and it may be that a specific pool is required for viral propagation. Thus, it is 
more important to the viral life cycle to retain the expression, and a high level of gene expression 
increase is required to compensate for protein degradation in these pools.  
It has been suggested that stabilisation of HPV genome replication is mediated by E6 interactions 
with PDZ proteins (Lee and Laimins, 2004; Nicolaides et al. 2011); such stabilisation may be a 
reason behind the viral requirement to maintain certain PDZ-protein presence in the cell.  
The increase in DLG1 gene expression upon HPV genome transfection is the highest of the 
PDZ-proteins investigated, and the reason for this is unclear. As part of the scribble complex, it 
may be that DLG1 upregulation is a cellular response to compensate for SCRIB protein 
downregulation also, seeing as SCRIB itself is not upregulated in response to depletion. 
The dependency of increased gene expression and/or decreased PDZ protein levels upon HPV 
E6 and the influence of other viral proteins can be investigated by expression of viral proteins 
singly, and in combination, with consequent gene and protein level analysis, using the HFK 
model. Analysis of individual viral oncoprotein expression would isolate the roles each factor 
played in the changes we see in PDZ-domain containing protein gene expression levels. Analysis 
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of protein levels would further elucidate the relationship between changes in gene expression and 
protein levels.  
In both expression analysis and qPCR data, HPV16 increases gene expression levels of DLG1, 
INADL and PTPN13 more than HPV18. In the case of DLG1, this difference is largest (Figure 
9, panel A), this may be linked to the ability of the virus to mediate protein degradation. 
Including different high-risk E6 types in HFKS and subjecting them to the expression analysis 
seen in this study would indicate whether E6 affinity for PDZ domain proteins affects the 
transformation ability of high-risk viruses, thus highlighting how dependant the carcinogenic 
activity of HPV16 and HPV18, as well as the life cycle of the virus, is upon the ability to bind a 
PDZ-protein preferentially over another. 
In contrast to early passage samples, expression of DLG1, INADL, PTPN13 and SCRIB in late 
passage (p3/p8) samples did not show change in expression levels upon HPV genome 
transfection (Figure 9 panel B). Further analysis of DLG1, INADL, PTPN13 and SCRIB at 
passages in between p3/p4 and p3/p8, as well as later passages if possible, would reveal the 
kinetics of their regulation. This variability could be a reflection of cell culture conditions at time 
of harvest; as DLG1, SCRIB and INADL are involved in TJ and adherens complexes that are 
sensitive to cell-cell interactions, their levels may be affected by confluency of cells in culture. 
Alternatively, the variability could reflect the progression of HPV infection through to 
immortalisation. At early passages, the keratinocytes resemble ‘normal’ infected basal cells, where 
E6 and E7 are driving cell proliferation and extend the life span of infected cells. Upon extended 
cell culture, the virus promotes immortalization of the cells and it can be said that this reflects a 
persistent HPV infection within the host. Keratinocyte immortalization may be driven by 
downregulation of PDZ proteins both at the transcriptional and translational levels, thus 
explaining the return of DLG1, INADL and PTPN13 gene expression to a normal level at later 
passages. 
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To study the effect of individual PDZ proteins, their depletion can be achieved by silencing gene 
expression and then compared to the phenotypic effects of HPV infection. To achieve this, an 
optimum set of shRNA combinations and conditions for silencing of DLG1 has been found, 
that will allow protein analysis of effects of the PDZ protein knockout, as has been demonstrated 
for PTPN13 (Javier and Rice, 2011). Now that the conditions for DLG1 silencing have been 
established, theses shRNAs can be used to investigate the effects of silencing DLG1 in human 
keratinocytes, and the resulting phenotype compared with E6 expressing cells. This principle of 
shRNA knockdown can be applied to the PDZ proteins INADL and PTPN13 in a keratinocyte 
system for similar investigations. 
4.1 Future Directions 
To investigate the hypothesis that HPV proteins work synergistically to decrease protein levels 
and/or increase gene expression of certain PDZ proteins, a comparison of the levels of DLG1 
INADL, PTPN13 and SCRIB proteins in HFKs transfected with HPV16 and HPV18 genomes 
with levels of gene expression could be carried out. If protein kinase A phosphorylates E6 to 
negatively regulate PBM interaction with PDZ-proteins, then no change in protein or transcript 
levels will be seen, so analysis of the phosphorylation state of E6 concurrent with analysis of 
PDZ-domain containing proteins could indicate how phosphorylation corresponds to the 
expression and translational levels of cellular PDZ proteins. Phosphorylation is a transient state, 
and is likely to vary at different stages of the cell cycle, and thus studying samples at each passage 
would be beneficial.  
As the viral mechanism of gene upregulation is unknown, an analysis of the expression of each 
viral protein on PDZ-domain protein gene expression would highlight whether E7, for example, 
is involved. It would then also be of interest to investigate the effect of co-expressing E7 and E6 
on the regulation of the PDZ protein transcription.  
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The findings of this study suggest that downregulation of the gene expression of these PDZ-
proteins might be involved in HPV induced immortalisation of keratinocytes. A further marker 
of cervical disease is integration of the viral genome into the host cell genome. The HPV genome 
is known to integrate into the genome of the keratinocyte cell lines used following extended 
passage of cells. Therefore, this cell model can be used to analyse the changes in expression of 
these cellular PDZ proteins before and after viral DNA integration. DNA analysis of cells would 
show whether integration of the HPV genome has an influence upon PDZ protein gene 
expression. Furthermore, use of different primary keratinocyte donors would both extend and 
strengthen the investigation.  
Moreover, PDZ protein expression profiles from clinical samples of cervical carcinomas at 
different stages would add layers of complexity over in vitro samples. Such studies would allow 
translation of our in vitro results to a disease phenotype, as well as highlighting other factors that 
may interact where the whole system is present, for example in vivo immune cells and growth 
factors. The HFK model of differentiation is a reliable model of HPV life cycle. Comparisons 
have been drawn between HPV-mediated oncogenesis of cervical and oropharyngeal mucosa 
(Shillitoe, 2009). Thus, it would be interesting to look at gene expression of PDZ proteins in 
head and neck cancer cell lines.  
This study shows the changes in DLG1, INADL, PTPN13 and SCRIB gene expression in a 
HFK model upon transfection with high-risk types of HPV. DLG1, INADL and PTPN13 gene 
expression is increased in cells replicating episomal HPV genomes, more so by HPV16 than by 
HPV18. The results are novel and create possibilities for further analysis. Study of the 
mechanism and consequences gene expression changes will perhaps provide insight into viral 
mechanisms of persistence and of oncogenesis. Research directed at understanding such virally-
induced oncogenesis and viral interactions with cell machinery highlights important cellular 
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oncoproteins and tumour suppressors, aids our knowledge of molecular events associated with 
human cancer and ultimately informs potential clinical and therapeutic outcomes. 
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Tables and Figures 
Table 3: Human Toll-like Receptors  
TLR Dimer 
Cellular 
Position 
Cell type Ligand(s) 
Herpesviruses 
known to 
have an 
affect/be 
affected 
References 
TLR 1 
Heterodimer 
with TLR2 
Cell surface 
Monocyte/macrophages, 
neutrophil 
Triacylated 
lipoproteins 
Peptidoglycan 
HCMV 
(envelope 
proteins) 
Boehme et al. 2006 
TLR 2 
Heterodimer 
with CD14, 
CD36, 
RP105 
Cell surface 
Mast cell 
monocyte/macrophage 
DC 
Hydrophobic 
PAMPs e.g. 
lipopeptides 
Diacylated 
lipoproteins 
HCMV 
(envelope 
proteins) 
EBV 
HSV-1 
Boehme et al. 2006 
Juckem et al. 2008 
Gaudreault et al. 2007 
Compton et al. 2003 
TLR 3 Homodimer Endosomal Conventional DC, B cell 
dsRNA 
ssRNA 
HSV 
EBV 
Alexopoulou et al. 
2001 
Zhou et al. 2009 
Iwakiri et al. 2009 
TLR 4 
Heterodimer
s with MD2, 
CD14, LBP, 
RP105 
Cell surface 
Monocytes/macrophage 
DC, mast cell, intestinal 
epithelial cell 
Lipopolysacchari
de 
Viral 
glycoproteins 
KSHV 
Burzyn et al. 2004 
Lagos et al. 2008 
TLR 5 Homodimer Cell surface 
Monocyte/macrophage a 
subset of DC, intestinal 
epithelial cell 
Bacterial 
flagellin 
- Hayashi et al. 2001 
TLR 
2/6 
TLR2/6 
heterodimer 
Cell surface 
Monocyte/macrophage 
mast cell, B cell 
Bacterial 
diacylated 
lipoproteins 
- 
Takeuchi et al. 1999 
Kang et al. 2009 
TLR 7 Homodimer Endosomal 
Monocyte/macrophage, 
pDC, B cell 
ssRNA 
VZV 
KSHV 
Heil et al. 2004 
Mancuso et al. 2009 
TLR 8 Homodimer Endosomal 
Monocyte/macrophage 
mast cell, pDC 
Viral ssRNA KSHV Gregory et al. 2009 
TLR 9 Homodimer Endosomal 
Monocyte/macrophage 
B cell, pDC 
Unmethylated 
DNA with CpG 
motif 
HSV-1 
MCMV 
MHV-67 
Krug et al. 2004 
TLR 10 did not form part of our analysis and therefore is not featured here. 
HSV - herpes simplex virus, HCMV- human cytomegalovirus, EBV- Epstein-Barr virus, KSHV - Kaposi’s sarcoma-
associated herpesvirus, MHV-68 - murine gammaherpesvirus 68, VZV - Varicella-Zoster virus. pDC - plasmacytoid 
dendritic cell 
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Figure 1: Virally-encoded Factors contributing to Host Cell Transformation 
Depiction from McLaughlin-Munger et al. 2008 showing the factors involved in the major biological activities that 
contribute to KSHV-mediated transformation. 
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Figure 2: TLR Signalling Pathways 
Cytoplasmic components of the TLR-activated signalling cascade overlap to initiate the transcription of genes 
required to recruit factors that drive the innate immune response. (from Carty and Bowie 2010). Upon stimulation by 
ligand, activated TLRs, except for TLR3, recruit MyD88. This adaptor protein binds the IRAK-4/IRAK-2/TRAF6 
complex which self-ubiquitinyates and activates a signalling cascade that results in the phosphorylation of TAK1.  
TAK1 activates the IKK complex, leading to the degradation of IκBa, allowing NFκB to translocate into the nucleus 
and transcribe genes, including those coding for pro-inflammatory cytokines. At the same time, TAK1 is able to 
activate the MAPK cascade, leading to activation of the transcription factor AP-1, which also induces pro-
inflammatory cytokine expression.  
TLR 3 bypasses MyD88 and recruits TRIF, an adaptor that interacts with the protein complex composed of 
TRADD, FADD and RIP-1. This complex triggers the activation of NFκB and AP-1. Activated TRIF binds TRAF3, 
leading to the activation of TBK1 and IKK-I, which phosphorylate IRF3, allowing its homodimerisation nuclear 
translocation. Along with NFκB and AP-1, IRF3 cooperates to induce type I IFN expression. 
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Figure 3: Expression of TLRs in TLR-transfected HEK-293 Cells 
RT PCR of mRNA extracted from uninfected HEK-293 cells expressing individual TLRs. Bands visualized on an 
agarose gel by ethidium bromide, to confirm the expression of TLRs in the correct cell lines, and the absence of TLR 
expression in control cell lines. Samples without the presence of reverse transcriptase enzyme show no bands, 
confirming that there is no DNA contamination in samples, and thus amplified fragments are derived from mRNA 
of expressed TLRs.  
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Figure 4: Fluorescence microscopy of infected cells at a range of MOIs 
Cells were plated at 2x105 cells, and infected the following day with rKSHV.219 with increasing MOIs. 48 hours 
post-infection, cells were visualised by fluorescence microscope and images captured using ImagePro. 
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Figure 5: Quantification of KSHV infection of TLR-expressing cell lines at different MOIs 
Infection efficiency is measured as the percentage of live cells expressing GFP. (A) The infection efficiency of all 
TLR-transfected cell lines compared to control HEK-293 cells, at five MOI values.  At MOIs of less than 5, such 
small amounts of virus are used that infection efficiency values are varied between experiments, and data is not 
consistent.  
(B) The infection efficiency of cell lines transfected with TLRs 1, 6, 7, 8 and 9 compared to control HEK-293 cells, 
at two MOI values. These are the cell lines that showed no difference in sensitivity to infection when compared to 
control cells. 
(C) The infection efficiency of cell lines transfected with TLRs 2, 3, 4 and 5 compared to control HEK-293 cells, at 
two MOI values. These are the cell lines that showed less sensitivity to infection compared to control cells. 
Data shown is the mean of at least three different experiments, error bars show standard deviation. 
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Figure 6: Comparative sq RT-PCR of TLR 3 in cell lines infected and uninfected with KSHV. 
Infected and uninfected cells expressing ectopic TLR 3 were subject to mRNA extraction and cDNA synthesis. This 
was then subject to PCR. 10ul aliquots were taken from the PCR reaction paused at 20, 25 and 33 cycles and run on 
an agarose gel for ethidium bomide detection. Images are taken under UV light. The brightest marker is the 500bp 
band, from a 100bp ladder (Invitrogen). 
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Figure 7: Comparative sq RT-PCR of TLR 4 in cell lines infected and uninfected with KSHV  
Infected and uninfected cells expressing TLR 4 ectopically were subject to mRNA extraction and cDNA synthesis. 
This was then subject to PCR. 10ul aliquots were taken from the PCR reaction paused at 20, 25 and 33 cycles and 
altogether run on an agarose gel for ethidium bomide detection. Images are taken under UV light. 
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Figure 8: Comparative semi-quantitative RT-PCR of TLR 5 in cell lines infected and uninfected with KSHV  
Infected and uninfected cells expressing TLR 5 ectopically were subject to mRNA extraction and cDNA synthesis. 
See Figure 6. The brightest marker is the 500bp band, from a 100bp ladder (Invitrogen). 
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Figure 9: Comparative semi-quantitative RT-PCR of TLR 7 in cell lines infected and uninfected with KSHV  
Infected and uninfected cells expressing ectopic TLR 7 were subject to mRNA extraction and cDNA synthesis. See 
Figure 6. The brightest marker is the 500bp band, from a 100bp ladder (Invitrogen). 
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Figure 3: Epithelial cell polarity 
Cell polarity is defined by the presence of tight junctions (TJs) and adherens junctions, which define the segregation 
of the cell membrane into apical and basolateral domains. Theses domains are both biochemically and functionally 
distinct. Three groups of proteins act to create and maintain apical-basal polarity: the scribble complex 
(Scribble/Dlg1/Lgl), the par complex (Par3/Par6/aPKC) and the crumbs complex (crumbs/PATJ/PALS). Polarity 
proteins are at the centre of various context-dependent signalling pathways. 
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Figure 4: Hallmarks of cancer 
Functional capabilities acquired by cancers during their development, via different mechanistic routes (Hanahan and 
Weinberg, 2000). 
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Figure 5: HPV maturation in epithelia 
The virus penetrates tissue via microabrasions and infects basal cells. Expression of E 6 and E7  induces cells to 
enter S phase and replicate, allowing concurrent replication of the viral genome. Amplification of viral genome and 
migration of cell eventually leads to synthesis and shedding of new viral particles. Adapted from Thomas et al. 2008. 
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Risk category Type PBM 
High-risk E6 HPV16 CMSCC-------RSSRTRRETQL 
HPV33 CAACW-------RS--RRRETAL 
HPV31 CIVCW---------RRPRTETQV 
HPV35 CMSCW---------KPTRRETEV 
HPV58 CAVCW---------RPRRRQTQV 
HPV52 CSECW----------RPRPVTQV 
HPV18 CHSCCNRARQE--RLQRRRETQV 
HPV45 CNTCCDQARQE--RLRRRRETQV 
HPV39 CRRCWTTKRED-RRLT-RRETQV 
HPV59 CRGCRTRARHLRQQRQARSETLV 
HPV56 CLGCW------RQTSREPRESTV 
HPV66 CLQCW------RHTSRQATESTV 
Low-risk E6 HPV6 CLHCWTTCMED---------MLP 
HPV11 CLHCWTTCMED---------LLP 
 
Figure 6: Structure of HPV E6 protein 
Schematic diagram of the structure of HPV E6 from Thomas et al. 2008. A) The protein consists of two zinc fingers, 
stabilised by intramolecular salt bridges between cysteine residues (highlighted in blue) and a highly conserved C-
terminus region (highlighted in green). B) High-risk HPV E6 oncoproteins contain a PDZ binding motif, whereas 
low-risk HPV E6 does not. (Area shaded in green). HPV = Human papillomavirus. 
TheHPV-16andHPV-18E6oncoproteinshavebeen
shown to interact, through this motif, with a large
number of PDZ domain-containing cellular substrates.
Ascanbeseen fromTable1, many of theseproteinsare
implicated in processes that regulate epithelial cell
polarity, underlining the importance of this pathway
both for viral replication and for virus-induced malig-
nancy. In the following discussion, weshall attempt to
highlight those interactions that, in our opinion, have
been themost extensively veriﬁed, and for which thereis
a clear role in the regulation of cell polarity. First,
however, weshall consider thebiological implicationsof
E6’sPDZ-binding capacity.
Biological consequencesof HPV E6 interaction
withPDZ-containing targets
Inmic
Many important insights into the biological effect of
HPV E6’sability to bind PDZ-containing targets have
been provided by a seriesof studies in transgenicmice,
in which theHPV-16 E6 and/or E7 oncoproteinswere
expressed from thekeratin 14promoter. Thispromoter
is activated in basal epithelium, thus ensuring that the
E6 and E7 proteins are expressed in a physiologically
relevant tissue (Arbeit et al., 1994; Herber et al., 1996;
Song et al., 1999). Mice expressing both oncoproteins
exhibited a high frequency of epithelial neoplasias
and also developed cervical cancer when treated
with oestrogen. Individual expression of either E6 or
E7 also resulted in skin tumours, but with interesting
HPV-16 : CMS CC-------RSSRTRRETQL
HPV-33 : CAA CW-------RS--RRRETAL
HPV-31 : CIV CW---------RRPRTETQV
HPV-35 : CMS CW----- KPTRRETE
HPV-58 : CAV CW---------RPRRRQTQV
HPV-52 : CSE CW----------RPRPVTQV
HPV-18 : CHS CCNRA QE--RLQRRRETQ
HPV-45 : CNT CCDQARQE RLRR RETQ
HPV-39 : CRR CWTTKRED-RRLT-RRETQV
HPV-59 : CRG CRTRARHLRQQRQARSETLV
HPV-56 : CLG CW------RQTSREPRESTV
HPV-66 : CLQ CW------RHTSRQATESTV
HP - 6 : CLH CWTTCMED---------MLP
HPV-11 : CLH CWTTCMED---------LLP
RhPV-1 : CPS C---------------ASRV
C C
CC
C C
C C
High-risk
E6
Low-risk
E6
High-risk
E7
Figure 2 The high-risk HPV E6 oncoproteins contain a PDZ
recognition motif. Schematic diagram showing the HPV E6
oncoprotein comprising two zinc ﬁngers, with a highly conserved
carboxy terminal tail. High-risk typesarethosefrequently found in
cervical cancers whereas the low-risk types are predominantly
found only in benign lesions. For comparison, RhPV-1 E7
oncoprotein is also shown. HPV, human papillomavirus; RhPV-1,
rhesuspapillomavirus type1.
Table1 PDZ-containing targetsof papillomavirusoncoproteins
PDZ-containing Targets of Papillomavirus Oncoproteins
FUNCTION
Cell polarity/tumour suppressor
Cell polarity/tumour suppressor 
Cell polarity/tumour suppressor 
PTEN localisation tomembrane
Signalling complex scaffold
TJ formation and integrity
Signalling complex scaffold
Protein tyrosine phosphatase
Non-receptor phosphatase
Down regulator of PDZ interactions
TGFb signalling 
Intracellular trafficking
Cell polarity/tumour suppressor
PROTEIN
Dlg
Scribble
MAGI-1
MAGI-2
MAGI-3
MUPP1
PATJ
PSD95
PTPH1/
PTPN3
PTPN13
TIP-1
TIP-2/GIPC
CAL
PAR3
EFFECT ON TARGET PROTEIN
ubiquitination and proteasomal degradation
ubiquitination and proteasomal degradation
ubiquitination and proteasomal degradation
ubiquitination and proteasomal degradation
ubiquitination and proteasomal degradation
plus E6*-directed degradation
ubiquitination and proteasomal degradation
ubiquitination and proteasomal degradation
?
?
ubiquitination and proteasomal degradation
ubiquitination and proteasomal degradation
ubiquitination and proteasomal degradation
plus relocalisation
REFERENCE
Gardiol et al. (1999)
Nakagawa and Huibregtse (2000)
Glaunsinger et al. (2000)
Thomas et al. (2002)
Lee et al. (2000)
Latorre et al. (2005)
Storrs and Silverstein (2007)
Handa et al. (2007)
Jing et al. (2007)
Töpffer et al. (2007)
Spanos et al. (2008b)
Hampson et al. (2004)
Favre-Bonvin et al. (2005)
Jeong et al. (2007)
Tomaic et al. (2008)
Human papillomaviruses, cervical cancer and cell polarity
MThomaset al
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Figure 7: Domain structure of PDZ-domain containing proteins. 
Each protein contains multiple PDZ domains, as well as other domains. The L27, Leucine rich repeats and SH3 
domains are involved in protein-protein interactions. The FERM domain of INADL binds plasma membrane and 
elements of the cytoskeleton. The GK domain of DLG1 is not functional. Different modules and catalytic domains 
allow the proteins to bring proteins together in a scaffold, and in the correct orientation for relevant catalysis. 
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 Figure 8: Optimisation of DLG1, INADL, PTPN13 and SCRIB specific primers 
cDNA was translated from DNase treated mRNA extracted from untransfected HFKs. At least three temperatures 
per primer pair were analysed, and a water control was included. Aliquots from each reaction were then run on a 2% 
agarose gel for ethidium bromide detection. A 100bp ladder (Invitrogen) was run alongside as a marker to indicate 
that the correct fragment was amplified. A) DLG1 and INADL B)PTPN13 C)SCRIB 
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Figure 9: qPCR: housekeeping gene comparison  
GAPDH, HPRT2 and B2M expression was analysed in untransfected HFKs and HPV16 and 18 transfected HFKs. 
Ct values are plotted to show the variation between each of the samples. Assays were performed in triplicate. 
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Figure 10: qPCR analysis of PDZ-domain containing proteins in HPV-transfected HFKs 
A) Analysis of cDNA from low passage samples, using mRNA from gene expression array. HPV 16 and 18 transfected HFKs at p3/p4 were normalised to untransfected HFKs 
(p3). B) Analysis of cDNA from high passage samples. HPV16 and 18 transfected HFs at p3/p8 were normalised to untransfected HFKs (p3). All assays were carried out in 
triplicates and results presented as 2-ΔΔCt values. Error bars show standard deviation of three experimental repeats. HPRT2 served as the housekeeping gene.  
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Figure 11: Silencing of DLG1 expression in H1299 cells 
ShRNA combinations were transfected into H1299 cells and incubated for 24 hours, before cells were harvested and protein extracted for Western blot analysis. The blot was 
exposed to film for 1 minute before fixing. Dlg1 and GAPDH band intensity was analysed by Image J software, comparing each lane to the loading control (GAPDH) and then 
normalising to GFP (Lane 1) intensity. 
Lane Name shRNA 
combinations 
GFP EGFP 
A 1 
B 2 
C 3 
D 4 
E 1 + 2  
F 1 + 3 
G 1 + 4 
H 1, 2 + 3 
I 1, 2, 3 + 4 
GAPDH 
DLG1 
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DLG1 
GAPDH 
shRNA Combinations 
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Figure 12: Time titration of selected shRNA combinations to knockdown of DLG1 in H1299 cells 
ShRNA combinations were transfected into H1299 cells and incubated for 12, 24, 48 or 72 hours, before cells were harvested and protein extracted for Western blot analysis. These 
blots were then exposed to film for 1 minute before fixing. DLG1 and GAPDH band intensity was analysed using the Image J program, comparing each lane to the loading control 
(GAPDH) and then normalising to GFP (Lane 1) intensity. Each lane of the blot below the graph corresponds to bar chart data, and the table indicates the content of each 
combination of shRNAs applied to cells. 
Lane Name shRNA 
combination 
GFP EGFP 
A 1 
B 4 
C 1 + 3 
D 1 + 4 
E 1, 2, 3 + 4 
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Table 4: HPV types 
HPV type Site of Infection Associated lesion Oncogenic Risk 
1, 4 Cutaneous skin Hand warts, verrucae Benign 
6, 11 Anogenital epithelia and 
laryngeal mucosa 
Genital warts, laryngeal 
papillomas 
Low 
16, 18, 33, 45 Anogenital epithelia and 
oropharyngeal mucosa 
CIN, anogenital cancers 
including cervical 
carcinoma, 
oropharyngeal cancer 
High 
5, 8, 38 Cutaneous skin Non-melanoma skin 
cancer 
High 
CIN = cerival intraepithelial neoplasia 
Taken from Roberts, S. and Young, L. (2008) HPV and disease.  In: Oxford Oncology Library - Vaccines for 
the Prevention of Cervical Cancer (eds. P. Stern and H. Kitchener).  Oxford University Press, pp 25-33 
[ISBN 978-019-954345-8]. 
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Table 5: PDZ domain-containing targets of papillomavirus oncoproteins 
Protein Function Effect of E6 on target Reference 
DLG1 
Cell polarity and 
integrity 
Ubiquitination and 
proteosomal degradation 
Gardiol et al. 1999 
Kiyono et al. 1997 
SCRIB 
Cell polarity and 
integrity 
Apoptotic signalling 
Ubiquitination and 
proteosomal degradation 
Nakagawa and Hulbregtse, 
2000 
MAGI-1, -2, -
3 
Cell polarity 
PTEN membrane 
localisation 
Ubiquitination and 
proteosomal degradation 
Glaunsinger et al. 2000 
Thomas et al. 2002 
MUPZ 
Signalling complex 
scaffold 
Ubiquitination and 
proteosomal degradation 
Lee et al. 2000 
INADL 
TJ formation and 
localisation 
Ubiquitination and 
proteosomal degradation 
E6* directed degradation 
Latorre et al. 2005 
Storrs and Silverstein, 2007 
DLG4 
Signalling complex 
scaffold 
Ubiquitination and 
proteosomal degradation 
Handa et al 2007 
PTPN3 Protein tyrosine kinase 
Ubiquitination and 
proteosomal degradation 
Jing et al. 2007 
Topffer et al. 2007 
PTPN13 
Non-receptor protein 
tyrosine phosphatase 
Apoptotic signalling 
Unknown Spanos et al. 2008 
TAX1BP3 
Downregulation of 
PDZ interactions 
Unknown Hampson et al. 2004 
GIPC1 TGFβ signalling 
Ubiquitination and 
proteosomal degradation 
Favre-Bonvin et al. 2005 
GOPC Intracellular trafficking 
Ubiquitination and 
proteosomal degradation 
Jeong et al. 2007 
PARD3 Cell polarity 
Ubiquitination and 
proteosomal degradation 
Relocalisation 
Tomalc et al. 2008 
Those highlighted are those focussed on in this report.  
DLG1- discs large 1, MAGI- membrane-associated guanylate kinase with inverted domains, MPDZ - multi-
PDZ domain protein 1, DLG4 - post-synaptic density protein 95, PTPN - protein tyrosine phosphatase, 
TAX1BP3 - tax-1 binding protein 3, GIPC1 - Golgi-associated PDZ and coiled-coil motif containing protein, 
GOPC - GAIP interacting protein C-terminus, PARD3 - par-3 partitioning defective 3 homologue. 
 E6* is a truncated form of E6, without the PBM motif. 
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Table 6: Gene expression array data   
Probe Set 
ID 
Gene 
Symbol 
Chromosomal 
Location 
fold 
change 
HPV 16 
fold 
change 
HPV 18 
Detection of 
transcript in 
HFK 
Detection of 
transcript with 
HPV16 
Detection of 
transcript with 
HPV18 
230229_at DLG1 3q29 11.67 7.50 Present Present Present 
214705_at INADL 1p31.3 4.47 2.58 Present Present Present 
243792_x_at PTPN13 4q21.3 4.22 4.40 Present Present Present 
212556_at SCRIB 8q24.3 1.57 2.01 Present Present Present 
213306_at MPDZ 9p24-p22 -1.79 1.27 Absent Absent Absent 
206144_at MAGI1 3p14.1 2.82 3.63 Absent Present Present 
207702_s_at MAGI2 7q21 -1.23 -2.08 Absent Absent Absent 
226770_at MAGI3 1p12-p11.2 2.13 1.57 Present Present Present 
204592_at DLG4 17p13.1 1.18 1.00 Present Absent Absent 
203997_at PTPN3 9q31 1.24 1.26 Present Present Present 
209154_at TAX1BP3 17p13 -1.75 -1.78 Present Present Present 
207525_s_at GIPC1 19p13.1 1.23 1.17 Present Present Present 
236862_at GOPC 6q21 22.07 16.94 Absent Absent  
221527_s_at PARD3 10p11.21 1.32 1.23 Present Present Present 
 
All proteins are PDZ-domain proteins. Gene expression of transfected HFKs at early passage (p3/p4) 
compared to untransfected HFKs (p3). From Woodman, Leonard, Roberts et al., unpublished data. 
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Table 7: shRNA constructs against DLG1 
Tube ID Nucleotide Sequence (5’-3’) Designated number 
TI353825 TCCTTGATGTGTCTGGAAATGCCATAAAG 1 
TI353826 GCAGCACATAAGGATGGCAAACTTCAGAT 2 
TI353827 GTAACTTCTAATGCCAGCGATAGTGAAAG 3 
TI353828 CAGAGCAACTCTTTCAGGCTTTAATAGA 4 
Every 29mer shRNA vector is cloned in pRS plasmid under U6 promoter for mammalian cell expression. 
Source: Origene Technologies Inc. Plasmids were transfected into H1299 cells using Lipofectamine in 
different combinations, referred to throughout experiments using the designated number.
  
 
Table 8: Primers used in qPCR 
 
 
mRNA 
amplification target  
Forward Primer  (5’-3’) Reverse  Primer  (5’-3’) Amplicon 
size (bp) 
DLG1 GCCCATTCCTAGCGCATGAACTCC GCCCATTCCTAGCGCATGAACTCC  101 
PTPN13 ATGAAACCTGTGCTAGGGATTATA     CGACCTCCCAGGCTCAAGTAG 286 
INADL/PATJ AGATCGGAGTTTTGCAGAGGT TCGAAGCAATGTTCTTGACCCA  100 
SCRIB CCTGCCAGCTCCAGCACCAC CGGCTGGGGTGGGGCAGTTA 147 
